

Data Set Name: tn01_additionalconsent.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of visit
3	Visit	Char	48		Visit
4	_22Jul2009VisitType	Char	37	\$37.	Visit type
5	_15Aug2011VisitType	Char	37	\$37.	Visit type
6	StorageOfResidualsDuringTrialN	Char	14	\$14.	Did participant consent to current storage of residual blood samples in the NIDDK repository during TrialNets existence
7	_15Aug2011ConsentForResidualSa	Char	7	\$7.	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
8	_22Jul2009ConsentSignedDay	Num	8		Date Informed Consent signed for 22July2009 protocol version day
9	_22Jul2009ConsentSignedMonth	Char	3	\$3.	Date Informed Consent signed for 22July2009 protocol version month
10	_22Jul2009ConsentSignedYear	Num	8		Date Informed Consent signed for 22July2009 protocol version year
11	_15Aug2011ConsentDateDay	Num	8		Date Informed Consent signed for 15Aug2011 protocol version day
12	_15Aug2011ConsentDateMonth	Char	3	\$3.	Date Informed Consent signed for 15Aug2011 protocol version month
13	_15Aug2011ConsentDateYear	Num	8		Date Informed Consent signed for 15Aug2011 protocol version year
14	Fall2017ConsentDateDay	Num	8		Date Informed Consent signed for Fall2017 protocol version day
15	Fall2017ConsentDateMonth	Char	3	\$3.	Date Informed Consent signed for Fall2017 protocol version month
16	Fall2017ConsentDateYear	Num	8		Date Informed Consent signed for Fall2017 protocol version year
17	_22Jul2009DPT1StorageConsent	Char	1	\$1.	On the Phase 3 Informed Consent form did the participant give permission for blood samples to be stored for future testing
18	_22Jul2009Phase2HLAConsent	Char	3	\$3.	On the Phase 2 Informed Consent form did the participant give permission for his/her blood to be tested for HLA genes
19	_22Jul2009Phase2StorageConsent	Char	3	\$3.	On the Phase 2 Informed Consent form did the participant give permission for storage of his/her samples for future testing
20	_22Jul2009Phase3StorageConsent	Char	3	\$3.	On the Phase 3 Informed Consent form did the participant give permission for blood samples to be stored for future testing
21	_22Jul2009ScreeningInformedCon	Char	7	\$7.	Did participant give permission for remaining blood samples to be stored for future testing as described in the informed consent form
22	WhichProtocolVersion	Char	12	\$12.	Which version of the Natural History protocol is your site using
23	WhyAccessingParticipantRecord	Char	71	\$71.	Why are you accessing this participant record
24	ProtocolVersion	Num	8		Protocol version
25	WhichProtocolVersion2	Char	16	\$16.	Which protocol version has the participant consented under
26	Spring2019ConsentDateMonth	Char	3	\$3.	Consent Date 2019 Protocol Version Month
27	Spring2019ConsentDateDay	Num	8		Consent Date 2019 Protocol Version Day
28	Spring2019ConsentDateYear	Num	8		Consent Date 2019 Protocol Version Year

Data Set Name: tn01_adverseevents.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit date
3	Visit	Char	48		Visit type
4	AdverseEventID	Num	8		Adverse Event ID
5	AETerm	Char	100		AE Term
6	severity	Num	8		Severity Index
7	AEReportType	Char	9		Adverse event report type
8	AEReportDtDay	Num	8		Adverse event report day
9	AEReportDtMonth	Num	8		Adverse event report month
10	AEReportDtYear	Num	8		Adverse event report year
11	AEOccurDtDay	Num	8		Adverse event occurrence day
12	AEOccurDtMonth	Num	8		Adverse event occurrence month
13	AEOccurDtYear	Num	8		Adverse event occurrence year
14	AEPrimarySecondary1_1	Char	9		Adverse event is primary or secondary
15	AECategory	Char	35		Adverse event category
16	AEDetails	Char	3999		Event details description
17	AETreatLocation	Char	14		Location of event treatment
18	AETreatLocationOther	Char	108		Location of event treatment if other
19	AEEExpected1_1	Char	3		Adverse event expected (per the IB or package insert with the exception of observational studies)
20	AECausalityByReporter	Char	22		Causality by reported relative
21	AEAssociations_Developmentofacon	Num	8		Development of a congenital anomaly or birth defect
22	AEAssociations_Developmentofaper	Num	8		Development of a permanent, serious, disabling or incapacitating condition
23	AEAssociations_Death	Num	8		Death
24	AEAssociations_Hospitalizationor	Num	8		Hospitalization or prolonged hospitalization
25	AEAssociations_Lifethreatening	Num	8		Life threatening
26	AEAssociations_Isanotherconditio	Num	8		Is another condition which investigators judge to represent significant hazards
27	AEPatientOutcome1_1	Char	35		Patient status
28	AEResolveDtDay	Num	8		Adverse event resolved day
29	AEResolveDtMonth	Num	8		Adverse event resolved month
30	AEResolveDtYear	Num	8		Adverse event resolved year
31	AEDateDeathDay	Num	8		Adverse event death day
32	AEDateDeathMonth	Num	8		Adverse event death month
33	AEDateDeathYear	Num	8		Adverse event death year
34	Comments	Char	3025		Additional comments
35	StudyDrugStartDateDay1_1	Num	8		Study drug start day
36	StudyDrugStartDateMonth1_1	Char	3		Study drug start month
37	StudyDrugStartDateYear1_1	Num	8		Study drug start year

Num	Variable	Type	Len	Format	Label
38	StudyDrugStopDateDay1_1	Num	8		Study drug stop day
39	StudyDrugStopDateMonth1_1	Char	3		Study drug stop month
40	StudyDrugStopDateYear1_1	Num	8		Study drug stop year
41	StudyDrugStartDateDay2_1	Num	8		Study drug start day
42	StudyDrugStartDateMonth2_1	Char	3		Study drug start month
43	StudyDrugStartDateYear2_1	Num	8		Study drug start year
44	StudyDrugStopDateDay2_1	Num	8		Study drug stop day
45	StudyDrugStopDateMonth2_1	Char	3		Study drug stop month
46	StudyDrugStopDateYear2_1	Num	8		Study drug stop year
47	StudyDrugStartDateDay3_1	Num	8		Study drug start day
48	StudyDrugStartDateMonth3_1	Char	3		Study drug start month
49	StudyDrugStartDateYear3_1	Num	8		Study drug start year
50	StudyDrugStopDateDay3_1	Num	8		Study drug stop day
51	StudyDrugStopDateMonth3_1	Char	3		Study drug stop month
52	StudyDrugStopDateYear3_1	Num	8		Study drug stop year
53	StudyDrugStartDateDay4_1	Num	8		Study drug start day
54	StudyDrugStartDateMonth4_1	Char	3		Study drug start month
55	StudyDrugStartDateYear4_1	Num	8		Study drug start year
56	StudyDrugStopDateDay4_1	Num	8		Study drug stop day
57	StudyDrugStopDateMonth4_1	Char	3		Study drug stop month
58	StudyDrugStopDateYear4_1	Num	8		Study drug stop year
59	StudyDrugStartDateDay5_1	Num	8		Study drug start day
60	StudyDrugStartDateMonth5_1	Char	3		Study drug start month
61	StudyDrugStartDateYear5_1	Num	8		Study drug start year
62	StudyDrugStopDateDay5_1	Num	8		Study drug stop day
63	StudyDrugStopDateMonth5_1	Char	1		Study drug stop month
64	StudyDrugStopDateYear5_1	Num	8		Study drug stop year
65	Eventabateafterstoppingdrug	Char	14		Event abated after stopping drug
66	Eventreappearafterreintrodukti	Char	14		Event appeared after drug reintroduction
67	AEFollowupDateDay	Num	8		Adverse event followup day
68	AEFollowupDateMonth	Num	8		Adverse event followup month
69	AEFollowupDateYear	Num	8		Adverse event followup year
70	AEReasonForFollowup	Char	55		Adverse event reason for followup
71	CentralIRBOrlocalIRB	Char	11		Central IRB or local IRB used for this protocol
72	AEFollowupNumber	Num	8		Adverse event followup number
73	AEOther	Num	8		Adverse event other
74	AEReporterStaffCode	Num	8		Adverse event reporter staff code
75	AESelectTerm	Num	8		Adverse event select term
76	centralIRBscriteria	Char	50		Central IRB criteria

Num	Variable	Type	Len	Format	Label
77	ElectronicSignature	Char	1		Adverse event electronic signature
78	AE Serious	Char	3		Serious adverse event

Data Set Name: tn01_adverseeventsreview.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	AECausalityByReviewer	Char	22	\$22.	Causality by reviewer
5	RecommendProtocolChange	Char	2	\$2.	Recommend changes to the protocol
6	RecommendConsentChange	Char	3	\$3.	Recommend changes to the consent form
7	AEReviewFormComments	Char	341	\$341.	Review form comments
8	AEAdditionalInfoRequested	Char	3	\$3.	Additional information requested
9	AEAdditionalInfoRequestedDetail	Char	499	\$499.	Adverse event additional information requested details
10	AEReviewRequireDSMBReview	Num	8		Requires urgent and immediate review by full DSMB committee
11	AEReviewDSMBReviewComments	Char	1	\$1.	Review requires DSMB review comments
12	AEReviewPriorSimilarSAEs	Char	3	\$3.	Have there been prior occurrences of similar reported in this study
13	AEReviewReportingTimeframe	Char	27	\$27.	Reporting time frame to regulatory authorities
14	AEReviewTreatmentUnblindedForC	Char	2	\$2.	Does treatment need to be unblinded for determination of causality
15	AEReviewPriorSimilarSAEsSummary	Char	280	\$280.	If prior occurrences of similar serious adverse events provide a brief summary
16	AEPatientOutcome	Char	1	\$1.	Patient outcome
17	AdverseEventID	Num	8		Adverse event ID

Data Set Name: tn01_autoantibodypositivept.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	DateofAssessmentDD	Num	8		Date of assessment day
5	DateofAssessmentMM	Char	3	\$3.	Date of assessment month
6	DateofAssessmentYYYY	Num	8		Date of assessment year
7	TN01ParticipantStatusSectionB	Char	56	\$56.	TN01 section b participant status section b
8	participantnoteligib_1Hasthepart	Num	8		Has the participant been diagnosed with type 1 diabetes (T1D)
9	participantnoteligib_2Hasthepart	Num	8		Has the participant previously used or is currently using medications for the control of hyperglycemia
10	participantnoteligib_3Doesthepar	Num	8		Does the participant have known severe active diseases, and/or diseases which are likely to limit life expectancy or lead to use of immunosuppressive or immunomodulatory therapies during the course of the study
11	participantnoteligib_4Doesthepar	Num	8		Does the participant currently use immunosuppressive or immunomodulatory therapies, including pharmacologic doses of systemic steroids
12	participantnoteligib_5Forfemales	Num	8		For females with child bearing age/potential, is the participant currently pregnant

Data Set Name: tn01_autoantibody_posfollowup.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	Followupstatuscode	Char	131		Followup status code

Data Set Name: tn01_cbcdifferential.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	DateOfBloodDrawDay	Num	8		Date of blood draw day
5	DateOfBloodDrawMonth	Char	3	\$3.	Date of blood draw month
6	DateOfBloodDrawYear	Num	8		Date of blood draw year
7	TimeOfCollectionHH	Num	8		Time of Collection hour
8	TimeOfCollectionMM	Num	8		Time of Collection minute
9	DateReportedDay	Num	8		Date results reported by lab day
10	DateReportedMonth	Char	3		Date results reported by lab month
11	DateReportedYear	Num	8		Date results reported by lab year
12	DateResultsReportedByLabUnknow	Num	8		Date results reported by lab Unknown
13	TimeResultsProcessedByLabHH	Num	8		Time Results Processed by Lab hour
14	TimeResultsProcessedByLabMM	Num	8		Time Results Processed by Lab minute
15	Rbcresults	Num	8		RBC results
16	Rbcnotdone	Num	8		RBC Not Done
17	RBCResultsNormal	Char	3	\$3.	RBC results normal
18	RBCResultAbormalClinicallySign	Char	3	\$3.	RBC results abnormal clinically significant
19	HemoglobinResults	Num	8		Hemoglobin Results
20	HemoglobinNotDone	Num	8		Hemoglobin Not Done
21	HemoglobinResultsNormal	Char	3	\$3.	Hemoglobin Results Normal
22	HemoglobinResultAbormalClinica	Char	3	\$3.	Hemoglobin results abnormal clinically significant
23	HematocritResults	Num	8		Hematocrit results
24	HematocritNotDone	Num	8		Hematocrit Not Done
25	HematocritResultsNormal	Char	3	\$3.	Hematocrit results normal
26	HematocritResultAbormalClinica	Char	3	\$3.	Hematocrit results abnormal clinically significant
27	MCVresults	Num	8		MCV results
28	MCVNotDone	Num	8		MCV Not Done
29	MCVresultsNormal	Char	3	\$3.	MCV results normal
30	MCVResultAbormalClinicallySign	Char	3	\$3.	MCV results abnormal clinically significant
31	PlateletCountResultsNormal	Num	8		Platelet count results
32	PlateletCountNotDone	Num	8		Platelet count Not Done
33	PlateletCountResultsNormal2	Char	3	\$3.	Platelet count results normal
34	PlateletCountResultAbormalClin	Char	3	\$3.	Platelet count results abnormal clinically significant
35	MCHresults	Num	8		MCH results
36	MCHNotDone	Num	8		MCH count Not Done
37	MCHresultsNormal	Char	3	\$3.	MCH results normal

Num	Variable	Type	Len	Format	Label
38	MCHResultAbormalClinicallySign	Char	3	\$3.	MCH results abnormal clinically significant
39	MCHCresults	Num	8		MCHC results
40	MCHCNotDone	Num	8		MCHC count Not Done
41	MCHCresultsNormal	Char	3	\$3.	MCHC results normal
42	MCHCResultAbormalClinicallySig	Char	3	\$3.	MCHC results abnormal clinically significant
43	WBCresults	Num	8		WBC results
44	WBCNotDone	Num	8		WBC Not Done
45	WBCresultsNormal	Char	3	\$3.	WBC results normal
46	WBCResultAbormalClinicallySign	Char	3	\$3.	WBC results abnormal clinically significant
47	NeutrophilsResults	Num	8		Neutrophils results
48	NeutrophilsResultsOR	Num	8		Neutrophils results OR
49	NeutrophilsNotDone	Num	8		Neutrophils Not Done
50	NeutrophilsResultsNormal	Char	3	\$3.	Neutrophils results normal
51	NeutrophilsResultAbormalClinic	Char	3	\$3.	Neutrophils results abnormal clinically significant
52	LymphocytesResults	Num	8		Lymphocytes results
53	LymphocytesResultsOR	Num	8		Lymphocytes results OR
54	LymphocytesNotDone	Num	8		Lymphocytes Not Done
55	LymphocytesResultsNormal	Char	3	\$3.	Lymphocytes results normal
56	LymphocytesResultAbormalClinic	Char	3	\$3.	Lymphocytes results abnormal clinically significant
57	MonocytesResults	Num	8		Monocytes results
58	MonocytesResultsOR	Num	8		Monocytes results OR
59	MonocytesNotDone	Num	8		Monocytes Not Done
60	MonocytesResultsNormal	Char	3	\$3.	Monocytes results normal
61	MonocytesResultAbormalClinical	Char	3	\$3.	Monocytes results abnormal clinically significant
62	EosinophilsResults	Num	8		Eosinophils results
63	EosinophilsResultsOR	Num	8		Eosinophils results OR
64	EosinophilsNotDone	Num	8		Eosinophils Not Done
65	EosinophilsResultsNormal	Char	3	\$3.	Eosinophils results normal
66	EosinophilsResultAbormalClinic	Char	3	\$3.	Eosinophils results abnormal clinically significant
67	BasophilsResults	Num	8		Basophils results
68	BasophilsResultsOR	Num	8		Basophils results OR
69	BasophilsNotDone	Num	8		Basophils Not Done
70	BasophilsResultsNormal	Char	3	\$3.	Basophils results normal
71	BasophilsResultAbormalClinical	Char	3	\$3.	Basophils results abnormal clinically significant

Data Set Name: tn01_changemonitoringschedule.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	MonitoringSchedulingChangeSemi	Num	8		Modify the participant schedule to include semiannual monitoring visits
5	MonitoringSchedulingChangeEffe	Num	8		Day change in schedule became effective
6	MonitoringSchedulingChangeEffe2	Char	3	\$3.	Month change in schedule became effective
7	MonitoringSchedulingChangeEffe3	Num	8		Year change in schedule became effective

Data Set Name: tn01_covid19ptassessment.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	Hasheparticipantbeentoahealth	Char	3	\$3.	1Has the participant been to a health clinic doctors office andor hospital for a sick visit
5	Hasheparticipantthadknownconta	Char	3	\$3.	2Has the participant had known contact with anyone with confirmed COVID19 since their previous study visitcontact
6	_2alfyes	Char	23	\$23.	2a If yes
7	Hasheparticipantthadknownconta2	Char	3	\$3.	3Has the participant had known contact with anyone with suspected COVID19 since their previous study visitcontact
8	_3alfyes	Char	23	\$23.	3alf yes
9	Hasheparticipantbeentestedfor	Char	3	\$3.	4Has the participant been tested for COVID19 since their previous study visitcontact
10	lfyesDateCOVID19TestAdminister	Num	8		If yes Date COVID19 Test Administered dd
11	lfyesDateCOVID19TestAdminister2	Char	3	\$3.	If yes Date COVID19 Test Administered MM
12	lfyesDateCOVID19TestAdminister3	Num	8		If yes Date COVID19 Test Administered YYYY
13	TypeofTestAdministered	Char	23	\$23.	4 If Yes Type of Test Administered
14	IfYesOutcomeofCOVID19Test	Char	16	\$16.	4 If Yes Outcome of COVID19 Test
15	Hasheparticipantthadafever	Char	3	\$3.	C1Has the participant had a fever
16	Whendidthefeveroccur	Char	16	\$16.	C1 When did the fever occur
17	WhatwasthemaximumtemperatureTe	Num	8		What was the maximum temperature Text
18	Whatwasthemaximumtemperature	Char	16	\$16.	What was the maximum temperature
19	Whatwastheduration	Num	8		1 What was the duration
20	WhatwasthedurationUnknownNotSu	Num	8		1 What was the durationUnknownNot Sure
21	Hasheparticipantthadchillsasso	Char	3	\$3.	2Has the participant had chills associated with fever
22	Whendidthechillsoccur	Char	16	\$16.	2 When did the chills occur
23	Whatwastheduration2	Num	8		2 What was the duration
24	WhatwasthedurationUnknownNotSu2	Num	8		2 What was the duration UnknownNot Sure
25	Hasheparticipantthadacough	Char	3	\$3.	3Has the participant had a cough
26	Whendidthecoughoccur	Char	16	\$16.	3 When did the cough occur
27	Whatwastheduration3	Num	8		3 What was the duration
28	WhatwasthedurationUnknownorNot	Num	8		3 What was the duration UnknownNot Sure
29	Whatwastheseverity	Char	45	\$45.	3 What was the severity
30	Hasheparticipantthadanydifficu	Char	3	\$3.	4Has the participant had any difficulty breathing or shortness of breath
31	Whendidthedifficultlybreathing	Char	16	\$16.	4 When did the difficulty breathing or shortness of breath occur
32	_4Whatwastheduration	Num	8		4 What was the duration
33	_4WhatwasthedurationUnknownNot	Num	8		4 What was the duration UnknownNot Sure
34	Whatwastheseverity2	Char	52	\$52.	4 What was the severity must select one
35	Hasheparticipantthadanypersist	Char	3	\$3.	5Has the participant had any persistent or prolonged fatigue

Num	Variable	Type	Len	Format	Label
36	Whendidthefatigueoccur	Char	16	\$16.	5When did the fatigue occur
37	Whatwastheduration4	Num	8		5What was the duration
38	WhatwasthedurationUnknownorNot2	Num	8		5What was the durationUnknownNot Sure
39	Whatwastheseverity3	Char	72	\$72.	5 What was the severity
40	Hastheparticipantthadalossreduc	Char	3	\$3.	6Has the participant had a lossreduction of their sense of taste andor smell
41	WhendidthelossreductionOccur	Char	16	\$16.	6 When did the lossreduction Occur
42	Whatwastheduration5	Num	8		6 What was the duration
43	WhatwasthedurationUnknownorNot3	Num	8		6 What was the duration UnknownNot Sure
44	Hastheparticipantexperiencedvo	Char	3	\$3.	7Has the participant experienced vomiting diarrhea headaches sore throat andor muscle aches
45	WhendidthesesympptomsOccur	Char	16	\$16.	7 When did these symptoms Occur
46	_7Selectallthatapply_Vomiting	Num	8		7Selectallthatapply: Vomiting
47	_7Selectallthatapply_Diarrhea	Num	8		7Selectallthatapply: Diarrhea
48	_7Selectallthatapply_Headaches	Num	8		7Selectallthatapply: Headaches
49	_7Selectallthatapply_SoreThroat	Num	8		7Selectallthatapply: Sore Throat
50	_7Selectallthatapply_MuscleAches	Num	8		7Selectallthatapply: Muscle Aches
51	_8Hastheparticipantbeendiagnos	Char	3	\$3.	8Has the participant been diagnosed with pneumonia
52	Whendidthepneumoniaoccur	Char	14	\$14.	8 When did the pneumonia occur
53	Whatwastheduration6	Num	8		8 What was the duration
54	WhatwasthedurationUnknownorNot4	Num	8		8 What was the duration UnknownNot Sure
55	AdditionalComments	Char	241	\$241.	9Additional Comments
56	Howlongwasthedurationofthepart	Num	8		D1How long was the duration of the participants COVID19 symptoms
57	Howlongwasthedurationofthepart2	Num	8		D1How long was the duration of the participants COVID19 symptoms UnknownNot Sure
58	WastheCOVID19diagnosissuspecte	Char	9	\$9.	D 2 Was the COVID19 diagnosis suspected by clinical symptoms or confirmed by testing
59	Wastheparticipanthospitalizeddd	Char	2	\$2.	D3Was the participant hospitalized due to COVID19
60	DatesparticipantinhospitalAdmi	Num	8		D 3 Dates participant in hospital Admitted DD
61	DatesparticipantinhospitalAdmi2	Char	1	\$1.	D 3 Dates participant in hospital Admitted MM
62	DatesparticipantinhospitalAdmi3	Num	8		D 3 Dates participant in hospital Admitted YYYY
63	DatesparticipantinhospitalAdmi4	Num	8		D 3 Dates participant in hospital Admitted Unknown
64	DatesparticipantinhospitalDisc	Num	8		D 3 Dates participant in hospital Discharged DD
65	DatesparticipantinhospitalDisc2	Char	1	\$1.	D 3 Dates participant in hospital Discharged MM
66	DatesparticipantinhospitalDisc3	Num	8		D 3 Dates participant in hospital Discharged YYYY
67	DatesparticipantinhospitalDisc4	Num	8		D 3 Dates participant in hospital Discharged Unknown
68	Wastheparticipanttreatedwithme	Char	2	\$2.	D 3 Was the participant treated with medications
69	WastheparticipantplacedintheIC	Char	2	\$2.	D 3 Was the participant placed in the ICU
70	Lengthoftime	Num	8		D 3 Length of time
71	LengthoftimeUnknownorNotSure	Num	8		D 3 Length of time UnknownNot Sure
72	Wastheparticipantplacedonavent	Char	2	\$2.	D 3 Was the participant placed on a ventilator

Num	Variable	Type	Len	Format	Label
73	Lengthoftime2	Num	8		D 3 Length of time
74	LengthoftimeUnknownorNotSure2	Num	8		D 3 Length of time UnknownNot Sure

Data Set Name: tn01_followupeligparticipant.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	IndicateTheStudyParticipantWas	Char	31		Please indicate which TrialNet study this participant was offered
5	IsParticipantCurrentlyEligible	Char	20		Is participant currently eligible
6	ParticipantWasContactedByOther	Char	49		Participant was contacted by other
7	IsTheParticipantInterested	Char	8		Is the participant interested in the selected study above
8	ReasonsNotInterested_Conflicting	Num	8		Reason participant is not currently interested in the study conflicting responsibilities
9	ConflictingResponsibilitiesRan	Char	20		Reason participant is not currently interested in the study conflicting responsibilities rank
10	ReasonsNotInterested_TimeCommitm	Num	8		Reason participant is not currently interested in the study time commitment
11	TimeCommitmentRank	Char	20		Reason participant is not currently interested in the study time commitment rank
12	UnableUnwillingToTravelRank	Char	20		Reason participant is not currently interested in the study unable unwilling to travel rank
13	ReasonsNotInterested_Participant	Num	8		Reason participant is not currently interested in the study participant does not tolerate OGTT IVGTTs well
14	DoesNotTolerateOGTTRank	Char	20		Reason participant is not currently interested in the study participant does not tolerate OGTT IVGTTs well rank
15	ReasonsNotInterested_FearofStudy	Num	8		Reason participant is not currently interested in the study fear of study drug risks
16	FearOfStudyDrugRisksRank	Char	20		Reason participant is not currently interested in the study fear of study drug risks rank
17	ReasonsNotInterested_Concernsabo	Num	8		Reason participant is not currently interested in the study concerns about receiving placebo
18	ConcernsAboutReceivingPlaceboR	Char	20		Reason participant is not currently interested in the study concerns about receiving placebo rank
19	ReasonsNotInterested_Familywithe	Num	8		Reason participant is not currently interested in the study family wishes to wait until participant is older
20	FamilyWishesToWaitUntilOlderRa	Char	20		Reason participant is not currently interested in the study family wishes to wait until participant is older rank
21	ReasonsNotInterested_Doesnotwant	Num	8		Reason participant is not currently interested in the study does not want to be blinded to individual test results during the study
22	DoesNotWantToBeBlindedRank	Char	16		Reason participant is not currently interested in the study does not want to be blinded to individual test results during the study rank
23	ReasonsNotInterested_Unwillingto	Num	8		Reason participant is not currently interested in the study unwilling to take investigational drug
24	UnwillingToTakeInvestigational	Char	20		Reason participant is not currently interested in the study unwilling to take investigational drug rank
25	ReasonsNotInterested_Pregnantnur	Num	8		Reason participant is not currently interested in the study pregnant nursing or planning children in the future
26	PregnantNursingOrPlanningChild	Char	16		Reason participant is not currently interested in the study pregnant nursing or planning children in the future rank
27	ReasonsNotInterested_MonetaryCom	Num	8		Reason participant is not currently interested in the study monetary compensation
28	MonetaryCompensationRank	Char	16		Reason participant is not currently interested in the study monetary compensation rank
29	ReasonsNotInterested_LosttoFollo	Num	8		Reason participant is not currently interested in the study lost to followup

Num	Variable	Type	Len	Format	Label
30	LostToFollowUp	Char	16		Reason participant is not currently interested in the study lost to followup rank
31	ReasonsNotInterested_Refusednore	Num	8		Reason participant is not currently interested in the study refused no reason given
32	ReasonsNotInterested_Other	Num	8		Reason participant is not currently interested in the study refused other
33	OtherRank	Char	20		Reason participant is not currently interested in the study refused other rank
34	ReasonsNotInterested_2DayInfusio	Num	8		Reason participant is not currently interested in the study 2 day infusion
35	_2DayInfusionPeriod	Char	1		Reason participant is not currently interested in the study 2 day infusion rank
36	ReasonsNotInterested_BiweeklyInj	Num	8		Reason participant is not currently interested in the study biweekly injection visit schedule
37	BiweeklyInjectionVisitSchedule	Char	16		Reason participant is not currently interested in the study biweekly injection visit schedule rank
38	ReasonsNotInterested_MonthlyInfu	Num	8		Reason participant is not currently interested in the study monthly infusion visit schedule
39	MonthlyInfusionVisitScheduleRa	Char	20		Reason participant is not currently interested in the study monthly infusion visit schedule rank
40	ReasonsNotInterested_2weekInfusi	Num	8		Reason participant is not currently interested in the study 2 week infusion period
41	_2WeekIfusionPeriodRank	Char	20		Reason participant is not currently interested in the study 2 week infusion period rank
42	willingToConsiderAtALaterTime	Char	3		Did the participant indicate they may be willing to consider participating in the study at a later time
43	ParticipantWasContac_AffiliateS1	Num	8		Participant was contacted by affiliate
44	ParticipantWasContac_AffiliateS2	Num	8		Participant was contacted by affiliate
45	ParticipantWasContac_ClinicalCe1	Num	8		Participant was contacted by clinical center
46	ParticipantWasContac_ClinicalCe2	Num	8		Participant was contacted by clinical center
47	ParticipantWasContac_Other	Num	8		Participant was contacted by other
48	ReasonsNotInterested_4weekInfusi	Num	8		ReasonsNotInterested: 4 week Infusion Period
49	ReasonsNotInterested_UnableUnwi1	Num	8		ReasonsNotInterested: Unable/ Unwilling to Travel
50	ReasonsNotInterested_UnableUnwi2	Num	8		ReasonsNotInterested: Unable/Unwilling to Complete Self-Administered Injections

Data Set Name: tn01_followupeligparticipant2.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Numeric	8	NONE	Participant Mask ID#
2	Visit_Dt	Numeric	8	MMDDYY10.	Visit Date
3	Visit	Character	48	NONE	Visit
4	Have there been any changes in the past months	Character	14	\$14.	Have there been any changes in the past months
5	Indicate which TrialNet study this participant was offered	Character	40	\$40.	Please indicate which TrialNet study this participant was offered
6	Indicate if the participant is a hot lead, warm lead or not eligible	Character	9	\$9.	Indicate if the participant is a hot lead, warm lead or not eligible
7	Participant is not eligible	Numeric	8	NONE	Participant is not eligible
8	_2cTN10Exclusion_1If18yoDiabetes	Numeric	8	NONE	2cTN10Exclusion: 1. If ?18yo: Diabetes, or have a screening OGTT with: a. Fasting plasma glucose ?126 mg/dL
9	_2cTN10Exclusion_1If18yoDiabetes2	Numeric	8	NONE	2cTN10Exclusion: 1. If ?18yo: Diabetes, or have a screening OGTT with: b. 2 hour plasma glucose ? 200mg/dL
10	_2cTN10Exclusion_2If<18yoDiabetes	Numeric	8	NONE	2cTN10Exclusion: 2. If <18yo: Diabetes, or have a screening random glucose ?200mg/dL
11	_2cTN10Exclusion_3Lymphopenia100	Numeric	8	NONE	2cTN10Exclusion: 3. Lymphopenia (< 1000 lymphocytes/?L)
12	_2cTN10Exclusion_4Neutropenia150	Numeric	8	NONE	2cTN10Exclusion: 4. Neutropenia (< 1500 PMN/?L)
13	_2cTN10Exclusion_5Thrombocytopen	Numeric	8	NONE	2cTN10Exclusion: 5. Thrombocytopenia (< 150,000 platelets/?L)
14	_2cTN10Exclusion_6AnemiaHgb10gra	Numeric	8	NONE	2cTN10Exclusion: 6. Anemia (Hgb < 10 grams/deciliter [g/dL])
15	_2cTN10Exclusion_7ASTorALT15xULN	Numeric	8	NONE	2cTN10Exclusion: 7. AST or ALT >1.5 x ULN
16	_2cTN10Exclusion_8Totalbilirubin	Numeric	8	NONE	2cTN10Exclusion: 8. Total bilirubin >1.5 x upper limit of normal (ULN) with the exception of subjects with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia
17	_2cTN10Exclusion_9INR01abovetheu	Numeric	8	NONE	2cTN10Exclusion: 9. INR > 0.1 above the upper limit of normal at the participating center's laboratory
18	_2cTN10Exclusion_10Chronicactive	Numeric	8	NONE	2cTN10Exclusion: 10. Chronic active infection other than localized skin infections
19	_2cTN10Exclusion_11ApositivePPDt	Numeric	8	NONE	2cTN10Exclusion: 11. A positive PPD test
20	_2cTN10Exclusion_12Vaccinationwi	Numeric	8	NONE	2cTN10Exclusion: 12. Vaccination with a live virus within 8 weeks of randomization
21	_2cTN10Exclusion_13Vaccinationwi	Numeric	8	NONE	2cTN10Exclusion: 13. Vaccination with a killed virus within 4 weeks of randomization
22	_2cTN10Exclusion_14Ahistoryofinf	Numeric	8	NONE	2cTN10Exclusion: 14. A history of infectious mononucleosis within the 3 months prior to enrollment
23	_2cTN10Exclusion_15Laboratoryorc	Numeric	8	NONE	2cTN10Exclusion: 15. Laboratory or clinical evidence of acute infection with EBV or CMV
24	_2cTN10Exclusion_16Serologicalev	Numeric	8	NONE	2cTN10Exclusion: 16. Serological evidence of current or past HIV, Hepatitis B or Hepatitis C infection
25	_2cTN10Exclusion_17Be currently pregnant	Numeric	8	NONE	2cTN10Exclusion: 17. Be currently pregnant or lactating, or anticipate getting pregnant
26	_2cTN10Exclusion_18Chronicuseof	Numeric	8	NONE	2cTN10Exclusion: 18. Chronic use of steroids or other immunosuppressive agents
27	_2cTN10Exclusion_19Ahistoryofasthma	Numeric	8	NONE	2cTN10Exclusion: 19. A history of asthma or atopic disease requiring chronic treatment
28	_2cTN10Exclusion_20Untreatedhyp	Numeric	8	NONE	2cTN10Exclusion: 20. Untreated hypothyroidism or active Graves disease at randomization
29	_2cTN10Exclusion_21Currentuseof	Numeric	8	NONE	2cTN10Exclusion: 21. Current use of non-insulin pharmaceuticals that affect glycemic control
30	_2cTN10Exclusion_22PriorOKT3or	Numeric	8	NONE	2cTN10Exclusion: 22. Prior OKT3 or other anti-CD3 treatment
31	_2cTN10Exclusion_23Administration	Numeric	8	NONE	2cTN10Exclusion: 23. Administration of a monoclonal antibody within the year before randomization
32	_2cTN10Exclusion_24Participation	Numeric	8	NONE	2cTN10Exclusion: 24. Participation in any type of therapeutic drug or vaccine clinical trial within the 12 weeks before randomization
33	_2cTN10Exclusion_25Anycondition	Numeric	8	NONE	2cTN10Exclusion: 25. Any condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the subject
34	TN10Exclusion25bDoesthiscondit	Character	3	\$3.	TN10 Exclusion 25bDoesthiscondit
35	_2cTN18Exclusion_1aAbnormalGluc1	Numeric	8	NONE	2cTN18Exclusion: 1a. Abnormal Glucose Tolerance or Diabetes (43,44) Fasting plasma glucose 110 mg/dL (6.1 mmol/L)
36	_2cTN18Exclusion_1aAbnormalGluc2	Numeric	8	NONE	2cTN18Exclusion: 1a. Abnormal Glucose Tolerance or Diabetes (43,44) 2 hour plasma glucose 140 mg/dL (7.8 mmol/L)
37	_2cTN18Exclusion_1aAbnormalGluc3	Numeric	8	NONE	2cTN18Exclusion: 1a. Abnormal Glucose Tolerance or Diabetes (43,44) 30, 60, 90 minute plasma glucose during OGTT 200 mg/dL (11.1 mmol/L)
38	_2cTN18Exclusion_2Insulinautoant	Numeric	8	NONE	2cTN18Exclusion: 2. Insulin autoantibodies (mIAA)

39	_2cTN18Exclusion_3Immunodeficient	Numeric	8	NONE	2cTN18Exclusion: 3. Immunodeficient or have clinically significant chronic lymphopenia
40	_2cTN18Exclusion_4Haveanactivein	Numeric	8	NONE	2cTN18Exclusion: 4. Have an active infection at time of randomization
41	_2cTN18Exclusion_5HaveapositiveP	Numeric	8	NONE	2cTN18Exclusion: 5. Have a positive PPD test result or history of previously treated TB, or positive interferon-gamma release assay (IGRA) test.
42	_2cTN18Exclusion_6Becurrentlypr	Numeric	8	NONE	2cTN18Exclusion: 6. Be currently pregnant or lactating, or anticipate getting pregnant within 3 months of the last study drug administration
43	_2cTN18Exclusion_7Useofmedicati	Numeric	8	NONE	2cTN18Exclusion: 7. Use of medications known to influence glucose tolerance
44	_2cTN18Exclusion_8Requireuseof	Numeric	8	NONE	2cTN18Exclusion: 8. Require use of other immunosuppressive agents
45	_2cTN18Exclusion_9Haveaserologic	Numeric	8	NONE	2cTN18Exclusion: 9. Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B core antibody or surface antigen), or Hepatitis C infection
46	_2cTN18Exclusion_10Haveaserologi	Numeric	8	NONE	2cTN18Exclusion: 10. Have serological evidence of current CMV infection
47	_2cTN18Exclusion_11Haveevidenc	Numeric	8	NONE	2cTN18Exclusion: 11. Have evidence of active EBV infection
48	_2cTN18Exclusion_12Haveanycom	Numeric	8	NONE	2cTN18Exclusion: 12. Have any complicating medical issues or abnormal clinical laboratory results
49	_2cTN18Exclusion_13Haveahist	Numeric	8	NONE	2cTN18Exclusion: 13. Have a history of malignancies
50	_2cTN18Exclusion_14HaveMultipl	Numeric	8	NONE	2cTN18Exclusion: 14. Have Multiple Sclerosis
51	TN18Exclusion12bDoesthiscondit	Character	3	\$3.	TN18 Exclusion 12bDoesthiscondit
52	TN16Exclusion_1Bedeemedunable	Numeric	8	NONE	TN16 Exclusion _1Bedeemedunableoru
53	_2cTN19Exclusion_1Beimmunodef	Numeric	8	NONE	2cTN19Exclusion: 1. Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (< 3,000 leukocytes), neutropenia (<1,500 neutrophils), lymphopenia (<800 lymphocytes), or thrombocytopenia (<100,000 platelets)
54	_2cTN19Exclusion_2Haveactivesig	Numeric	8	NONE	2cTN19Exclusion: 2. Have active signs or symptoms of acute infection at the time of randomization
55	_2cTN19Exclusion_3Haveevidenc	Numeric	8	NONE	2cTN19Exclusion: 3. Have evidence of prior or current tuberculosis infection as assessed by PPD, interferon gamma release assay or by history
56	_2cTN19Exclusion_4Becurrentlypr	Numeric	8	NONE	2cTN19Exclusion: 4. Be currently pregnant or lactating, or anticipate getting pregnant within the two year study period
57	_2cTN19Exclusion_5Requireuseof	Numeric	8	NONE	2cTN19Exclusion: 5. Require use of other immunosuppressive agents including chronic use of systemic steroids
58	_2cTN19Exclusion_6Haveevidenc	Numeric	8	NONE	2cTN19Exclusion: 6. Have evidence of current or past HIV, Hepatitis B or Hepatitis C infection
59	_2cTN19Exclusion_7Haveanycomp	Numeric	8	NONE	2cTN19Exclusion: 7. Have any complicating medical issues or abnormal clinical laboratory results
60	_2cTN19Exclusion_8Haveahist	Numeric	8	NONE	2cTN19Exclusion: 8. Have a history of malignancies other than skin
61	_2cTN19Exclusion_9Evidenceofliv	Numeric	8	NONE	2cTN19Exclusion: 9. Evidence of liver dysfunction with AST or ALT greater than 3 times the upper limits of normal
62	_2cTN19Exclusion_10Evidenceofre	Numeric	8	NONE	2cTN19Exclusion: 10. Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal
63	_2cTN19Exclusion_11Vaccination	Numeric	8	NONE	2cTN19Exclusion: 11. Vaccination with a live virus within the last 6 weeks
64	_2cTN19Exclusion_12Currentor	Numeric	8	NONE	2cTN19Exclusion: 12. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening
65	_2cTN19Exclusion_13Activeparti	Numeric	8	NONE	2cTN19Exclusion: 13. Active participation in another T1D treatment study in the previous 30 days
66	_2cTN19Exclusion_14Priortreat	Numeric	8	NONE	2cTN19Exclusion: 14. Prior treatment with abatacept or anti-cd3
67	_2cTN19Exclusion_15Knownallerg	Numeric	8	NONE	2cTN19Exclusion: 15. Known allergy to GCSF or ATG
68	_2cTN19Exclusion_16Priortreat	Numeric	8	NONE	2cTN19Exclusion: 16. Prior treatment with ATG or known allergy to rabbit derived products
69	_2cTN19Exclusion_17Anycondit	Numeric	8	NONE	2cTN19Exclusion: 17. Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results
70	TN19Exclusion17bDoesthiscondit	Character	1	\$1.	TN19 Exclusion 17bDoesthiscondit
71	TN22ExclusionCriteri_AbnormalGl	Numeric	8	NONE	TN22 Exclusion Criteri_AbnormalGlu
72	TN22ExclusionCriteri_Historyof	Numeric	8	NONE	TN22 Exclusion Criteri_Historyoftr
73	TN22ExclusionCriteri_Ongoinguse	Numeric	8	NONE	TN22 Exclusion Criteri_Ongoinguseo
74	TN22ExclusionCriteri_Ongoingora	Numeric	8	NONE	TN22 Exclusion Criteri_Ongoingoran
75	TN22ExclusionCriteri_Knownhyper	Numeric	8	NONE	TN22 Exclusion Criteri_Knownhypers
76	TN22ExclusionCriteri_G6PDdeficie	Numeric	8	NONE	TN22 Exclusion Criteri_G6PDdeficie
77	TN22ExclusionCriteri_Historyofre	Numeric	8	NONE	TN22 Exclusion Criteri_Historyofre
78	TN22ExclusionCriteri_Activeinfec	Numeric	8	NONE	TN22 Exclusion Criteri_Activeinfec
79	TN22ExclusionCriteri_Serologic	Numeric	8	NONE	TN22 Exclusion Criteri_Serologic

80	TN22ExclusionCriteri_Deemedunlik	Numeric	8	NONE	TN22 Exclusion Criteri_Deemedunlik
81	_2cTN23ExclusionCrite_1Inability	Numeric	8	NONE	2cTN23ExclusionCrite: 1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
82	_2cTN23ExclusionCrite_2Historyof	Numeric	8	NONE	2cTN23ExclusionCrite: 2. History of clinically significant anemia or Hemoglobin <10 g/dl.
83	_2cTN23ExclusionCrite_3Evidenceo	Numeric	8	NONE	2cTN23ExclusionCrite: 3. Evidence of liver dysfunction, with alanine aminotransferase (ALT) > 2.5 times the upper limit of normal or aspartate aminotransferase (AST) >3.0 times the upper limit of normal persistent for 1 week or greater.
84	_2cTN23ExclusionCrite_4Historyof	Numeric	8	NONE	2cTN23ExclusionCrite: 4. History of renal insufficiency or serum creatinine of >1.5 times the upper limit of normal.
85	_2cTN23ExclusionCrite_5Historyof	Numeric	8	NONE	2cTN23ExclusionCrite: 5. History of symptomatic hypotension including positional hypotension.
86	_2cTN23ExclusionCrite_6SystolicB	Numeric	8	NONE	2cTN23ExclusionCrite: 6. Systolic BP < 100 mmHg for adults or blood pressure < 5th percentile for age/height/gender in children and adolescents
87	_2cTN23ExclusionCrite_7Useofatre	Numeric	8	NONE	2cTN23ExclusionCrite: 7. Use of a treatment that is known to cause a significant, ongoing change in the course of diabetes or immunologic status, within 4 weeks prior to participation. This includes high-dose inhaled, extensive topical or systemic glucocor
88	_2cTN23ExclusionCrite_8Femaleswh	Numeric	8	NONE	2cTN23ExclusionCrite: 8. Females who are pregnant at the time of screening, breastfeeding or unwilling to defer pregnancy during the 16-month study period. (Female participant must be at least 100 days postpartum before enrollment into study).
89	_2cTN23ExclusionCrite_9Unableto	Numeric	8	NONE	2cTN23ExclusionCrite: 9. Unable to avoid concurrent antihypertensive medications, monoamine oxidase (MAO) inhibitors, lithium, or medications containing ferrous sulfate or ferrous gluconate.
90	_2cTN23ExclusionCrite_10Unablet	Numeric	8	NONE	2cTN23ExclusionCrite: 10. Unable to avoid medications that affect stomach pH, such as proton pump inhibitors or histamine H2 receptor blockers.
91	_2cTN23ExclusionCrite_11Pastorcu	Numeric	8	NONE	2cTN23ExclusionCrite: 11. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above
92	_2cTN20Exclusion_1Diagnosedwit	Numeric	8	NONE	2cTN20Exclusion: 1. Diagnosed with Diabetes or having their most recent OGTT with fasting glucose ?126 mg/dl or 2 hour glucose ? 200 mg/dl
93	_2cTN20Exclusion_2Priorparticipa	Numeric	8	NONE	2cTN20Exclusion: 2. Prior participation in clinical research for secondary prevention of T1D
94	_2cTN20Exclusion_3Historyofreat	Numeric	8	NONE	2cTN20Exclusion: 3. History of treatment with insulin or oral hypoglycemic agent
95	_2cTN20Exclusion_4Currentchroni	Numeric	8	NONE	2cTN20Exclusion: 4. Current chronic use of medications altering stomach acid (such as H2 blockers, proton pump inhibitors and antacids)
96	_2cTN20Exclusion_5Historyofgastr	Numeric	8	NONE	2cTN20Exclusion: 5. History of gastric ulcer or gastric surgery
97	_2cTN20Exclusion_6Historyofthera	Numeric	8	NONE	2cTN20Exclusion: 6. History of therapy with immunosuppressive drugs or non-physiologic glucocorticoids within the past two years for a period of more than three months
98	_2cTN20Exclusion_7Hassevereacti	Numeric	8	NONE	2cTN20Exclusion: 7. Has severe active disease, e.g. chronic active hepatitis, severe cardiac, pulmonary, renal, hepatic, immune deficiency
99	_2cTN20Exclusion_8Ongoinguseof	Numeric	8	NONE	2cTN20Exclusion: 8. Ongoing use of medications known to influence glucose tolerance
100	_2cTN20Exclusion_9Pregnantinten	Numeric	8	NONE	2cTN20Exclusion: 9. Pregnant, intends to become pregnant while on study, or lactating
101	_2cTN20Exclusion_10Deemedunlik	Numeric	8	NONE	2cTN20Exclusion: 10. Deemed unlikely or unable to comply with the protocol or have any complicating medical issues or abnormal clinical laboratory results that interfere with study conduct or cause increased risk
102	TN20Exclusion10bDoesthiscondit	Character	1	\$1.	TN20 Exclusion 10bDoesthiscondit
103	TN16TN19TN20EligibilityStatus	Character	20	\$20.	TN16TN19TN20EligibilityStatus
104	Pleaseselecttypeofcontactattem	Character	26	\$26.	Please select type of contact made
105	_2dMailedLetter	Character	3	\$3.	_2dMailedLetter
106	_2dMailedLetterWhyNot	Character	157	\$157.	_2dMailedLetterWhyNot
107	DateParticipantwascontacted1_1	Numeric	8	NONE	Date participant was contacted
108	DateParticipantwascontacted1_2	Character	3	\$3.	Date participant was contacted
109	DateParticipantwascontacted1_3	Numeric	8	NONE	Date participant was contacted
110	ParticipantWasCo_AffiliateSi1_1	Numeric	8	NONE	Affiliate site participant was contacted by
111	ParticipantWasCo_AffiliateSi1_2	Numeric	8	NONE	Affiliate site participant was contacted by
112	ParticipantWasCo_ClinicalCen1_1	Numeric	8	NONE	Clinical center participant was contacted by
113	ParticipantWasCo_ClinicalCen1_2	Numeric	8	NONE	Clinical center participant was contacted by
114	ParticipantWasCo_Other1_1	Numeric	8	NONE	Participant was contacted by other
115	ParticipantWasContactedByOt1_1	Character	166	\$166.	Participant was contacted by other specify
116	MethodofContactA_Telephone1_1	Numeric	8	NONE	Method of contact: Telephone
117	MethodofContactA_Email1_1	Numeric	8	NONE	Method of contact: Email
118	MethodofContactA_Mail1_1	Numeric	8	NONE	Method of contact: Mail
119	MethodofContactA_Other1_1	Numeric	8	NONE	Method of contact: Other
120	MethodofContactAttemptOther1_1	Character	251	\$251.	Method of contact: Other specify
121	FinalContactAttempt1_1	Character	3	\$3.	Final contact attempt
122	Istheparticipantinterestedinth	Character	17	\$17.	Is the participant interested in the study selected in question 1
123	ReasonsNotInterested_Conflicting	Numeric	8	NONE	Reason participant is not currently interested in the study conflicting responsibilities
124	ReasonsNotInterested_TimeCommit	Numeric	8	NONE	Reason participant is not currently interested in the study time commitment
125	ReasonsNotInterested_Participant	Numeric	8	NONE	Reason participant is not currently interested in the study participant does not tolerate OGTT IVGTTs well
126	ReasonsNotInterested_FearofStudy	Numeric	8	NONE	Reason participant is not currently interested in the study fear of study drug risks
127	ReasonsNotInterested_Concernsabo	Numeric	8	NONE	Reason participant is not currently interested in the study concerns about receiving placebo

128	ReasonsNotInterested_Familywise	Numeric	8	NONE	Reason participant is not currently interested in the study family wishes to wait until participant is older
129	ReasonsNotInterested_Doesnotwant	Numeric	8	NONE	Reason participant is not currently interested in the study does not want to be blinded to individual test results during the study
130	ReasonsNotInterested_Unwillingto	Numeric	8	NONE	Reason participant is not currently interested in the study unwilling to take investigational drug
131	ReasonsNotInterested_Pregnantnur	Numeric	8	NONE	Reason participant is not currently interested in the study pregnant nursing or planning children in the future
132	ReasonsNotInterested_MonetaryCom	Numeric	8	NONE	Reason participant is not currently interested in the study monetary compensation
133	ReasonsNotInterested_Other	Numeric	8	NONE	Reason participant is not currently interested in the study refused other
134	ReasonsNotInterested_LosttoFollo	Numeric	8	NONE	Reason participant is not currently interested in the study lost to followup
135	ReasonsNotInterested_Refusednore	Numeric	8	NONE	Reason participant is not currently interested in the study refused no reason given
136	ReasonsNotInterested_2DayInfusio	Numeric	8	NONE	Reason participant is not currently interested in the study 2 day infusion
137	ReasonsNotInterested_2weekInfusi	Numeric	8	NONE	Reason participant is not currently interested in the study 2 week infusion period
138	ReasonsNotInterested_BiweeklyInj	Numeric	8	NONE	Reason participant is not currently interested in the study biweekly injection visit schedule
139	ReasonsNotInterested_MonthlyInfu	Numeric	8	NONE	Reason participant is not currently interested in the study monthly infusion visit schedule
140	Didtheparticipantindicatetheym	Character	14	\$14.	Did the participant indicate they may be willing to consider participating in the study at a later time
141	LONG_DESCRIPTION	Character	18	\$18.	Long description
142	SHORT_DESCRIPTION	Character	18	\$18.	short description
143	revised_short_desc_checkbox	Character	31	\$31.	Revised short description checkbox
144	revised_long_description	Character	16	\$16.	Revised long description
145	Pleasespecify	Character	1	\$1.	TN25 2c if YES Please specify
146	EFFECTIVE_DATE	Numeric	8	DATETIME20.	Effective date
147	TERMINATION_DATE	Numeric	8	DATETIME20.	Termination date
148	ReasonsNotInterested_4weekInfusi	Numeric	8	NONE	ReasonsNotInterested: 4 week Infusion Period
149	ReasonsNotInterested_UnableUnwi1	Numeric	8	NONE	ReasonsNotInterested: Unable/ Unwilling to Travel
150	ReasonsNotInterested_UnableUnwi2	Numeric	8	NONE	ReasonsNotInterested: Unable/Unwilling to Complete Self-Administered Injections
151	_2cTN25Exclusion_10Notuptodateo	Numeric	8	NONE	2cTN25Exclusion: 10. Not up-to-date on current immunizations.
152	_2cTN25Exclusion_11Laboratoryor	Numeric	8	NONE	2cTN25Exclusion: 11. Laboratory or clinical evidence of acute infection with EBV or CMV, either via serology or PCR.
153	_2cTN25Exclusion_12Serologicale	Numeric	8	NONE	2cTN25Exclusion: 12. Serological evidence of current or past HIV, Hepatitis B or Hepatitis C infection.
154	_2cTN25Exclusion_13Have severeo	Numeric	8	NONE	2cTN25Exclusion: 13. Have severe obesity: adults BMI > 40; children BMI-z score > 2.0.
155	_2cTN25Exclusion_14Be currentlyp	Numeric	8	NONE	2cTN25Exclusion: 14. Be currently pregnant or lactating, or anticipate getting pregnant within 2 years and 4 months of enrollment
156	_2cTN25Exclusion_15Chronicuseof	Numeric	8	NONE	2cTN25Exclusion: 15. Chronic use of steroids or other immunosuppressive agents.
157	_2cTN25Exclusion_16Knownandunt	Numeric	8	NONE	2cTN25Exclusion: 16. Known and untreated hypothyroidism or active Graves disease at enrollment.
158	_2cTN25Exclusion_17Administrati	Numeric	8	NONE	2cTN25Exclusion: 17. Administration of a monoclonal antibody within the year before enrollment.
159	_2cTN25Exclusion_18Historyofmal	Numeric	8	NONE	2cTN25Exclusion: 18. History of malignancy.
160	_2cTN25Exclusion_19Useofexogen	Numeric	8	NONE	2cTN25Exclusion: 19. Use of exogenous insulin or any other anti-hyperglycemic drugs.
161	_2cTN25Exclusion_1Diabetes	Numeric	8	NONE	2cTN25Exclusion: 1. Diabetes
162	_2cTN25Exclusion_20Anyconditio	Numeric	8	NONE	2cTN25Exclusion: 20. Any condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the participant
163	_2cTN25Exclusion_2Immunodefici	Numeric	8	NONE	2cTN25Exclusion: 2. Immunodeficient or have clinically significant chronic lymphopenia
164	_2cTN25Exclusion_3Requireuseof	Numeric	8	NONE	2cTN25Exclusion: 3. Require use of other immunosuppressive agents
165	_2cTN25Exclusion_4Chronicactivei	Numeric	8	NONE	2cTN25Exclusion: 4. Chronic active infection other than localized skin infections.
166	_2cTN25Exclusion_5Activeinfectio	Numeric	8	NONE	2cTN25Exclusion: 5. Active infection at the time of infusion.
167	_2cTN25Exclusion_6ApositivePPD	Numeric	8	NONE	2cTN25Exclusion: 6. A positive PPD or Quantiferon test, or history of previous treatment for TB.
168	_2cTN25Exclusion_7Vaccinationwi	Numeric	8	NONE	2cTN25Exclusion: 7. Vaccination with a live virus within 4 weeks prior to enrollment.
169	_2cTN25Exclusion_8Vaccinationwi	Numeric	8	NONE	2cTN25Exclusion: 8. Vaccination with a killed virus within 4 weeks prior to enrollment.
170	_2cTN25Exclusion_9Ahistoryofcon	Numeric	8	NONE	2cTN25Exclusion: 9. A history of confirmed infectious mononucleosis within the 3 months prior to enrollment, as documented by EBV serology.

Data Set Name: tn01_glycemicstatusassessment.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	Informationgatheredfrom	Char	23	\$23.	1Information gathered from check one
5	InformationgatheredfromOtherTe	Char	1	\$1.	1Information gathered from OtherText
6	MethodofContact	Char	12	\$12.	2Method of Contact check one
7	MethodofContactOtherTextbox	Char	1	\$1.	2Method of Contact OtherTextbox
8	Hasthesubjectprovidedcontinued	Char	3	\$3.	3 Has the subject provided continued consent to participate in the study at this visit
9	Hasthesubjectexperiencedblurre	Char	3	\$3.	1 Has the subject experienced blurred vision
10	Hasthesubjectexperiencedpolyur	Char	3	\$3.	2Has the subject experienced polyuria
11	Hasthesubjectexperiencedpolydy	Char	3	\$3.	3Has the subject experienced polydipsia
12	Hasthesubjectexperienceduninte	Char	3	\$3.	4 Has the subject experienced unintended weight loss
13	HasthesubjecthadanepisodeofDKA	Char	2	\$2.	1 Has the subject had an episode of DKA since the previous visit
14	lfyesDD	Num	8		alf yes DD
15	lfyesMM	Char	1	\$1.	alf yes MM
16	lfyesYYYY	Num	8		alf yes YYYY

Data Set Name: tn01_locallabresults.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	DatebloodsamplewasdrawnDay	Num	8		Date blood sample was drawn Day
5	DatebloodsamplewasdrawnMonth	Char	3	\$3.	Date blood sample was drawn Month
6	DatebloodsamplewasdrawnYear	Num	8		Date blood sample was drawn Year
7	GADAResult	Num	8		GADA Result
8	GADAUnits	Char	11	\$11.	GADA Units
9	GADAUnitsOtherText	Char	29	\$29.	GADA Units Other Text
10	GADAInterpretation	Char	8	\$8.	GADA Interpretation
11	GADAPositivityThreshold	Char	21	\$21.	GADA Positivity Threshold
12	GADAPositivityThresholdTextVal	Num	8		GADA Positivity Threshold Text Value
13	GADANotDone	Num	8		GADA Not Done
14	mIAAIAAResult	Num	8		mIAAIAA Result
15	mIAAIAAUnits	Char	11	\$11.	mIAAIAA Units
16	mIAAIAAUnitsOtherText	Char	7	\$7.	mIAAIAA Units Other Text
17	mIAAIAAInterpretation	Char	8	\$8.	mIAAIAA Interpretation
18	mIAAIAAPositivityThreshold	Char	21	\$21.	mIAAIAA Positivity Threshold
19	mIAAIAAPositivityThresholdText	Num	8		mIAAIAA Positivity Threshold Text Value
20	mIAAIAANotDone	Num	8		mIAAIAA Not Done
21	IA2AResult	Num	8		IA2A Result
22	IA2AUnits	Char	11	\$11.	IA2A Units
23	IA2AUnitsOtherText	Char	48	\$48.	IA2A Units Other Text
24	IA2AInterpretation	Char	8	\$8.	IA2A Interpretation
25	IA2APositivityThreshold	Char	21	\$21.	IA2A Positivity Threshold
26	IA2APositivityThresholdTextVal	Num	8		IA2A Positivity Threshold Text Value
27	IA2ANotDone	Num	8		IA2A Not Done
28	ZnT8AResult	Num	8		ZnT8A Result
29	ZnT8AUnits	Char	11	\$11.	ZnT8A Units
30	ZnT8AUnitsOtherText	Char	1	\$1.	ZnT8A Units Other Text
31	ZnT8AInterpretation	Char	8	\$8.	ZnT8A Interpretation
32	ZnT8APositivityThreshold	Char	21	\$21.	ZnT8A Positivity Threshold
33	ZnT8APositivityThresholdTextVa	Num	8		ZnT8A Positivity Threshold Text Value
34	ZnT8ANotDone	Num	8		ZnT8A Not Done
35	ICAResult	Num	8		ICA Result
36	ICAUnits	Char	5	\$5.	ICA Units
37	ICAUnitsOtherText	Char	11	\$11.	ICA Units Other Text

Num	Variable	Type	Len	Format	Label
38	ICAInterpretation	Char	8	\$8.	ICA Interpretation
39	ICAPositivityThreshold	Char	21	\$21.	ICA Positivity Threshold
40	ICAPositivityThresholdTextValu	Num	8		ICA Positivity Threshold Text Value
41	ICANotDone	Num	8		ICA Not Done

Data Set Name: tn01_nh01f_familyhistory.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	NumOfRelativesWithT1D	Num	8		How many of the participants blood relatives have type 1 diabetes including deceased relatives
5	RelativeWithT1D1_1	Char	22	\$22.	Relative with Type 1 Diabetes
6	SexOfRelativeWithT1D1_1	Char	6	\$6.	Sex of Relative
7	AgeOfRelativeWithT1D1_1	Num	8		Current Age of Relative
8	AgeOfOnsetInRelativeWithT1D1_1	Num	8		Age of Onset in Relative
9	AgeRelativeWithT1DStartedIn1_1	Num	8		Age Relative Started Insulin
10	RelativeComments1_1	Char	165	\$165.	Relative Comments
11	RelativeWithT1D2_1	Char	22	\$22.	Relative with Type 1 Diabetes
12	SexOfRelativeWithT1D2_1	Char	6	\$6.	Sex of Relative
13	AgeOfRelativeWithT1D2_1	Num	8		Current Age of Relative
14	AgeOfOnsetInRelativeWithT1D2_1	Num	8		Age of Onset in Relative
15	AgeRelativeWithT1DStartedIn2_1	Num	8		Age Relative Started Insulin
16	RelativeComments2_1	Char	186	\$186.	Relative Comments
17	RelativeWithT1D3_1	Char	22	\$22.	Relative with Type 1 Diabetes
18	SexOfRelativeWithT1D3_1	Char	6	\$6.	Sex of Relative
19	AgeOfRelativeWithT1D3_1	Num	8		Current Age of Relative
20	AgeOfOnsetInRelativeWithT1D3_1	Num	8		Age of Onset in Relative
21	AgeRelativeWithT1DStartedIn3_1	Num	8		Age Relative Started Insulin
22	RelativeComments3_1	Char	141	\$141.	Relative Comments
23	RelativeWithT1D4_1	Char	22	\$22.	Relative with Type 1 Diabetes
24	SexOfRelativeWithT1D4_1	Char	6	\$6.	Sex of Relative
25	AgeOfRelativeWithT1D4_1	Num	8		Current Age of Relative
26	AgeOfOnsetInRelativeWithT1D4_1	Num	8		Age of Onset in Relative
27	AgeRelativeWithT1DStartedIn4_1	Num	8		Age Relative Started Insulin
28	RelativeComments4_1	Char	141	\$141.	Relative Comments
29	RelativeWithT1D5_1	Char	22	\$22.	Relative with Type 1 Diabetes
30	SexOfRelativeWithT1D5_1	Char	6	\$6.	Sex of Relative
31	AgeOfRelativeWithT1D5_1	Num	8		Current Age of Relative
32	AgeOfOnsetInRelativeWithT1D5_1	Num	8		Age of Onset in Relative
33	AgeRelativeWithT1DStartedIn5_1	Num	8		Age Relative Started Insulin
34	RelativeComments5_1	Char	100	\$100.	Relative Comments
35	RelativeWithT1D6_1	Char	22	\$22.	Relative with Type 1 Diabetes
36	SexOfRelativeWithT1D6_1	Char	6	\$6.	Sex of Relative
37	AgeOfRelativeWithT1D6_1	Num	8		Current Age of Relative

Num	Variable	Type	Len	Format	Label
38	AgeOfOnsetInRelativeWithT1D6_1	Num	8		Age of Onset in Relative
39	AgeRelativeWithT1DStartedIn6_1	Num	8		Age Relative Started Insulin
40	RelativeComments6_1	Char	69	\$69.	Relative Comments
41	RelativeWithT1D7_1	Char	17	\$17.	Relative with Type 1 Diabetes
42	SexOfRelativeWithT1D7_1	Char	6	\$6.	Sex of Relative
43	AgeOfRelativeWithT1D7_1	Num	8		Current Age of Relative
44	AgeOfOnsetInRelativeWithT1D7_1	Num	8		Age of Onset in Relative
45	AgeRelativeWithT1DStartedIn7_1	Num	8		Age Relative Started Insulin
46	RelativeComments7_1	Char	46	\$46.	Relative Comments
47	RelativeWithT1D8_1	Char	17	\$17.	Relative with Type 1 Diabetes
48	SexOfRelativeWithT1D8_1	Char	6	\$6.	Sex of Relative
49	AgeOfRelativeWithT1D8_1	Num	8		Current Age of Relative
50	AgeOfOnsetInRelativeWithT1D8_1	Num	8		Age of Onset in Relative
51	AgeRelativeWithT1DStartedIn8_1	Num	8		Age Relative Started Insulin
52	RelativeComments8_1	Char	27	\$27.	Relative Comments
53	RelativeWithT1D9_1	Char	14	\$14.	Relative with Type 1 Diabetes
54	SexOfRelativeWithT1D9_1	Char	6	\$6.	Sex of Relative
55	AgeOfRelativeWithT1D9_1	Num	8		Current Age of Relative
56	AgeOfOnsetInRelativeWithT1D9_1	Num	8		Age of Onset in Relative
57	AgeRelativeWithT1DStartedIn9_1	Num	8		Age Relative Started Insulin
58	RelativeComments9_1	Char	20	\$20.	Relative Comments
59	RelativeWithT1D10_1	Char	13	\$13.	Relative with Type 1 Diabetes
60	SexOfRelativeWithT1D10_1	Char	6	\$6.	Sex of Relative
61	AgeOfRelativeWithT1D10_1	Num	8		Current Age of Relative
62	AgeOfOnsetInRelativeWithT1D10_1	Num	8		Age of Onset in Relative
63	AgeRelativeWithT1DStartedIn10_1	Num	8		Age Relative Started Insulin
64	RelativeComments10_1	Char	10	\$10.	Relative Comments
65	RelativeWithT1D11_1	Char	13	\$13.	Relative with Type 1 Diabetes
66	SexOfRelativeWithT1D11_1	Char	6	\$6.	Sex of Relative
67	AgeOfRelativeWithT1D11_1	Num	8		Current Age of Relative
68	AgeOfOnsetInRelativeWithT1D11_1	Num	8		Age of Onset in Relative
69	AgeRelativeWithT1DStartedIn11_1	Num	8		Age Relative Started Insulin
70	RelativeComments11_1	Char	10	\$10.	Relative Comments
71	RelativeWithT1D12_1	Char	8	\$8.	Relative with Type 1 Diabetes
72	SexOfRelativeWithT1D12_1	Char	4	\$4.	Sex of Relative
73	AgeOfRelativeWithT1D12_1	Num	8		Current Age of Relative
74	AgeOfOnsetInRelativeWithT1D12_1	Num	8		Age of Onset in Relative
75	AgeRelativeWithT1DStartedIn12_1	Num	8		Age Relative Started Insulin
76	RelativeComments12_1	Char	8	\$8.	Relative Comments

Num	Variable	Type	Len	Format	Label
77	RelativeWithT1D13_1	Char	8	\$8.	Relative with Type 1 Diabetes
78	SexOfRelativeWithT1D13_1	Char	4	\$4.	Sex of Relative
79	AgeOfRelativeWithT1D13_1	Num	8		Current Age of Relative
80	AgeOfOnsetInRelativeWithT1D13_1	Num	8		Age of Onset in Relative
81	AgeRelativeWithT1DStartedIn13_1	Num	8		Age Relative Started Insulin
82	RelativeComments13_1	Char	8	\$8.	Relative Comments
83	RelativeWithT1D14_1	Char	8	\$8.	Relative with Type 1 Diabetes
84	SexOfRelativeWithT1D14_1	Char	4	\$4.	Sex of Relative
85	AgeOfRelativeWithT1D14_1	Num	8		Current Age of Relative
86	AgeOfOnsetInRelativeWithT1D14_1	Num	8		Age of Onset in Relative
87	AgeRelativeWithT1DStartedIn14_1	Num	8		Age Relative Started Insulin
88	RelativeComments14_1	Char	8	\$8.	Relative Comments

Data Set Name: tn01_nh01_screening.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	Visit_Type	Char	16		Visit Type
5	ScreeningDay	Num	8		Screening Day
6	ScreeningMonth	Char	3	\$3.	Screening Month
7	ScreeningYear	Num	8		Screening year
8	Age	Num	8		Age
9	RelativeWithT1D	Char	3	\$3.	Do you have a relative with T1D
10	DegreeOfRelative_1st	Num	8		Degree of relative: 1st
11	DegreeOfRelative_2ndor3rd	Num	8		Degree of relative: 2nd or 3rd
12	HaveDiabetes	Char	3	\$3.	Do you have diabetes
13	ParticipantLocation	Char	14	\$14.	Please indicate participant location
14	BirthMonth	Char	3	\$3.	Participant Birth Month
15	BirthYear	Num	8		Participant Birth Year
16	Sex	Char	6	\$6.	Participant Sex
17	Ethnicity	Char	22	\$22.	Participant Ethnicity
18	Race_AmericanIndianorAlaskaNat	Num	8		Race: American Indian or Alaska Native
19	Race_Asian	Num	8		Race: Asian
20	Race_BlackorAfricanAmerican	Num	8		Race: Black or African American
21	Race_NativeHawaiianorOtherPaci	Num	8		Race: Native Hawaiian or Other Pacific Islander
22	Race_Refused	Num	8		Race: Refused
23	Race_Unknownornotreported	Num	8		Race: Unknown or not reported
24	Race_White	Num	8		Race: White
25	Relationship	Char	11	\$11.	Relationship to participant
26	FirstHearAboutTrialN_ExistingTri	Num	8		How did you first hear about TrialNet: Existing TrialNet Site
27	FirstHearAboutTrialN_FamilyFrien	Num	8		How did you first hear about TrialNet: Family/Friend
28	FirstHearAboutTrialN_Brochure	Num	8		How did you first hear about TrialNet: Brochure
29	FirstHearAboutTrialN_Healthcarep	Num	8		How did you first hear about TrialNet: Health care professional
30	FirstHearAboutTrialN_Tollfreepho	Num	8		How did you first hear about TrialNet: Toll free phone number
31	FirstHearAboutTrialN_NewspaperMa	Num	8		How did you first hear about TrialNet: Newspaper/Magazine
32	FirstHearAboutTrialN_Poster	Num	8		How did you first hear about TrialNet: Poster
33	FirstHearAboutTrialN_Camp	Num	8		How did you first hear about TrialNet: Camp
34	FirstHearAboutTrialN_MeetingPres	Num	8		How did you first hear about TrialNet: Meeting/Presentation
35	FirstHearAboutTrialN_RadioTV	Num	8		How did you first hear about TrialNet: Radio/TV
36	FirstHearAboutTrialN_Internet	Num	8		How did you first hear about TrialNet: Internet
37	FirstHearAboutTrialN_Other	Num	8		How did you first hear about TrialNet: Other

Num	Variable	Type	Len	Format	Label
38	InitialScreeningLocation	Char	26	\$26.	Where did initial screening blood draw occur
39	InitialScreeningLocationOtherS	Char	80	\$80.	Where did initial screening blood draw occur other specify
40	_15Aug2011ConsentForResidualSa	Char	7	\$7.	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
41	BloodSamplesFutureTestingPermi	Char	7	\$7.	Did participant give permission for remaining blood samples to be stores for future testing as described in the informed consent form
42	BloodTestForFindOut	Char	73	\$73.	This blood test is being done to find out if
43	CommunicationWhenNegAutoantibo	Char	62	\$62.	If you are negative for autoantibodies we will inform you via
44	InformedTestResultWithin	Char	9	\$9.	We will let you know your test results within a duration of your blood draw
45	PermissionToControllfTheyTestA	Char	7	\$7.	Did participant give permission on the informed consent form to be a control if they test autoantibody negative
46	participanthaveautoantibodies	Char	3	\$3.	4 Has the participant been found to have autoantibodies outside of TrialNet testing
47	OnlineScreeningReferralSource	Char	28	\$28.	Online screening referral site
48	ConsentSignedDay	Num	8		Informed consent signed day
49	ConsentSignedMonth	Char	3	\$3.	Informed consent signed month
50	ConsentSignedYear	Num	8		Informed consent signed year
51	DateSignedInformedConsentFormM	Char	3	\$3.	Date participant signed the Monitoring Informed Consent Form Month 2017
52	DateSignedInformedConsentFormD	Num	8		Date participant signed the Monitoring Informed Consent Form day 2017
53	DateSignedInformedConsentFormY	Num	8		Date participant signed the Monitoring Informed Consent Form Year 2017
54	DateSignedNEWInformedConsentFo2	Char	3	\$3.	Date signed NEW informed consent form Month
55	DateSignedNEWInformedConsentFo	Num	8		Date signed NEW informed consent form Day
56	DateSignedNEWInformedConsentFo3	Num	8		Date signed NEW informed consent form Year
57	clinicalcenternumber	Num	8		Regional clinical center number
58	ScreeningSiteName	Char	100	\$100.	Screening site name
59	ScreeningSiteNumber	Num	8		Screening site number
60	WhichProtocolVersion	Char	16	\$16.	Which protocol version has the participant consented under
61	shipspecimencollectionkit	Char	3	\$3.	Would you like the TrialNet Coordinating Center to ship an autoantibody specimen collection kit to the participant
62	Specimencollectionkitshipmentd	Char	10	\$10.	Specimen collection kit shipment date
63	FamilyMemberFirstName10_1	Char	1	\$1.	12 Does the participant have any other family members screening today First Name
64	FmailMemberLasttName10_1	Char	1	\$1.	12 Does the participant have any other family members screening today Last Name
65	Spring2019ConsentDateMonth	Char	3	\$3.	Consent Date 2019 Protocol Version Month
66	selecttestkittype	Char	12	\$12.	2If yes please select test kit type
67	FamilyMembersDOBMonth10_1	Char	1	\$1.	12Does the participant have any other family members screening today Month
68	Spring2019ConsentDateDay	Num	8		Consent Date 2019 Protocol Version Day
69	Spring2019ConsentDateYear	Num	8		Consent Date 2019 Protocol Version Year
70	FamilyMemberDay10_1	Num	8		12 Does the participant have any other family members screening today Day DD
71	FamilyMemberYear10_1	Num	8		12Does the participant have any other family members screening today Year

Data Set Name: tn01_nh04_baselinriskassess.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	Visit_Type	Char	16		Visit Type
5	ParticipantDiagnosedWithT1D	Char	3	\$3.	Has the participant been diagnosed with type 1 diabetes T1D
6	ParticipantUsedInsulinOrOtherG	Char	3	\$3.	Has the participant ever previously used or is currently using medications for the control of hyperglycemia eg insulin oral hypoglycemic agents including sulfonylureas metformin thiazolidinediones alphaglucoisidase inhibitors meglitinides GLP1 mimetics and
7	ParticipantHasKnownSevereActiv	Char	3	\$3.	Does the participant have known severe inactive diseases andor diseases which are likely to limit life expectancy or lead to use of immunosuppressive or immunomodulatory therapies during the course of the study
8	ParticipantPregnant	Char	14	\$14.	Is the participant knowingly pregnant
9	PermissionForHLAgeneticTesting	Char	3	\$3.	Permission for his/her blood to be tested for HLA genes
10	PermissionForSampleStorage	Char	3	\$3.	Storage of his/her samples for future testing
11	DateConsentSignedDay	Num	8		Date signed informed consent form day
12	DateConsentSignedMonth	Char	3	\$3.	Date signed Informed Consent form month
13	DateConsentSignedYear	Num	8		Date signed Informed Consent form year
14	AsthmaEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has asthma ever
15	AsthmaWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has asthma
16	CeliacDiseaseEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has celiac disease ever
17	CeliacDiseaseWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has celiac disease
18	InflammatoryBowelDiseaseEver	Char	3		Has the participant been told by a physician that they he/she has inflammatory bowel disease ever
19	InflammatoryBowelDiseaseWithin	Char	3		Has the participant been told by a physician that they he/she has inflammatory bowel disease within the last year
20	AddisonsDiseaseEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has addisons disease ever
21	AddisonsDiseaseWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has Addisons disease
22	VitiligoEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has vitiligo ever
23	VitiligoWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has vitiligo
24	ThyroidDiseaseEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has thyroid disease ever
25	ThyroidDiseaseWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has thyroid disease
26	PsoriasisEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has psoriasis ever
27	PsoriasisWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has psoriasis
28	AlopeciaEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has alopecia ever
29	AlopeciaWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has alopecia
30	RheumatologicEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has rheumatologic disease ever
31	RheumatologicWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has rheumatologic disease

Num	Variable	Type	Len	Format	Label
32	MultipleSclerosisEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has multiple sclerosis ever
33	MultipleSclerosisWithinLastYea	Char	3	\$3.	Has the participant been told by a physician that they he/she has multiple sclerosis
34	OtherAutoimmuneDiseasesEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has other autoimmune disease ever
35	OtherAutoimmuneDiseasesWithinL	Char	3	\$3.	Has the participant been told by a physician that they he/she has other autoimmune diseases
36	SeatedArmBPSystolic	Num	8		Collect the following assessments Seated arm blood pressure systolic
37	SeatedArmBPDiastolic	Num	8		Collect the following assessments Seated arm blood pressure Diastolic
38	Weightkg	Num	8		Collect the following assessments Weight in kgs
39	Weightlbs	Num	8		Collect the following assessments Weight in lbs
40	Heightcm	Num	8		Collect the following assessments Height in cm
41	Heightin	Num	8		Collect the following assessments Height in inches
42	EverParticipatedInPreventionSt	Char	3	\$3.	Has the participant ever participated in a prevention study for T1D
43	SpecifyStudyForPreventionOfT1D	Char	54	\$54.	Has the participant ever participated in a prevention study for T1D If Yes name of study studies
44	ParticipateInDPT1	Char	3	\$3.	Did the participant participate in DPT1
45	DPT1ParticipantIDNumber	Char	30	\$30.	Did the participant participate in DPT1 if Yes record the DPT1 participant ID number
46	AllergiesEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has allergies ever
47	AllergiesWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has allergies
48	AntibodySampleCollected	Char	3	\$3.	Antibodies sample collected
49	BetaBlockers	Char	3	\$3.	Is the participant taking beta blockers
50	BlloodForDNASampleCollected	Char	3	\$3.	Blood for DNA sample collected
51	BloodForCellsSampleCollected	Char	3	\$3.	Blood for cells sample collected
52	BloodForRNASampleCollected	Char	3	\$3.	Blood for RNA sample collected
53	CancerEver	Char	3	\$3.	Has the participant ever be
54	CancerWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has cancer
55	ColitisOrColonProblemsEver	Char	3	\$3.	Colitis or colon problems ever
56	ColitisOrColonProblemsWithinLa	Char	3	\$3.	Has the participant been told by a physician that they he/she has colitis or colon problems
57	CongenitalHeartDiseaseEver	Char	3	\$3.	Congenital heart disease or heart problems ever
58	CongenitalHeartDiseaseWithinLa	Char	3	\$3.	Has the participant been told by a physician that they he/she has congenital heart disease
59	ConsenToContinuedStorageOfBlo	Char	14	\$14.	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
60	Corticosteroids	Char	3	\$3.	Is the participant taking corticosteroids
61	Diphenylhydantoin	Char	3	\$3.	Is the participant taking diphenylhydantoin
62	EpilepsyConvulsionsSeizuresEve	Char	3	\$3.	Epilepsy convulsions or seizures ever
63	EpilepsyConvulsionsSeizuresWit	Char	3	\$3.	Has the participant been told by a physician that they he/she has epilepsy convulsions or seizures
64	HLASamplesCollected	Char	3	\$3.	HLA sample collected
65	HbA1cSamplesCollected	Char	3	\$3.	HbA1c sample collected
66	HepatitisOrLiverDiseaseEver	Char	3	\$3.	Hepatitis Liver disease ever

Num	Variable	Type	Len	Format	Label
67	HepatitisOrLiverDiseaseWithinL	Char	3	\$3.	Has the participant been told by a physician that they he/she has hepatitis or liver disease
68	HighBPever	Char	3	\$3.	High blood pressure ever
69	HighBPwithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has high blood pressure
70	HighcholesterolEver	Char	3		High Cholesterol ever
71	IVGTTSampleCollected	Char	3	\$3.	IVGTT sample collected
72	ImmunosuppressiveTherapies	Char	3	\$3.	Is the participant taking immunosuppressive therapies
73	InfectiousMononucleosisEver	Char	3	\$3.	Infectious mononucleosis ever
74	InfectiousMononucleosisWithinL	Char	3	\$3.	Has the participant been told by a physician that they he/she has infectious mononucleosis
75	Niacin	Char	3	\$3.	Is the participant taking niacin
76	OGTTSampleCollected	Char	3	\$3.	OGTT sample collected
77	ParticipantHasOneRelativeWithT	Char	3	\$3.	Does the participant have at least one blood relative living or deceased with type 1 diabetes T1D
78	ParticipantUsedImmunosuppressiv	Char	2	\$2.	Does the participant currently use immunosuppressive or immunomodulatory therapies including pharmacologic doses of systemic steroids
79	ParticipantUsingImmunosuppressi	Char	3	\$3.	Is the participant currently using immunosuppressive or immunomodulatory therapies or systemic glucocorticoids
80	PerniciousAnemiaEver	Char	3	\$3.	Pernicious anemia ever
81	PerniciousAnemiaWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has pernicious anemia
82	PlasmaSampleCollected	Char	3	\$3.	Plasma Sample Collected
83	PotassiumDepletingDiurectics	Char	3	\$3.	Is the participant taking potassium depleting diuretics
84	SerumForProteomicsSampleCollec	Char	3	\$3.	Sample collected for serum proteomics
85	UlcerEver	Char	3	\$3.	Ulcer stomach or duodenal ever
86	UlcerWithinLastYear	Char	3	\$3.	Has the participant been told by a physician that they he/she has ulcer
87	Antibodycomment	Char	79	\$79.	Antibodies Comment
88	BetaBlockersSpecify	Char	43	\$43.	Is the participant taking beta blockers specify
89	BlloodForDNAComment	Char	100	\$100.	Blood for DNA comment
90	BloodForCellsComment	Char	133	\$133.	Blood for cells comment
91	BloodForRNAComment	Char	133	\$133.	Blood for RNA comment
92	HLAComment	Char	183	\$183.	HLA comment
93	HbA1cComment	Char	79	\$79.	HbA1c comment
94	IVGTTComment	Char	80	\$80.	IVGTT Comment
95	ImmunosuppressiveTherapiesSpec	Char	25	\$25.	Is the participant taking immunosuppressive therapies specify
96	OGTTComment	Char	153	\$153.	OGTT comment
97	OtherAutoimmuneDiseasesSpecify	Char	78	\$78.	Has the participant been told by a physician that they he/she has other autoimmune diseases specify
98	ParticipantUsedInsulinOrOtherG2	Char	93	\$93.	If yes specify
99	PlasmaComment	Char	133	\$133.	Plasma Sample comment
100	PotassiumDepletingDiurecticsSp	Char	22	\$22.	Is the participant taking potassium depleting diuretics specify
101	SerumForProteomicsComment	Char	133	\$133.	Serum for proteomics comment
102	SteroidsSpecify	Char	90	\$90.	Is the participant taking steroids specify

Num	Variable	Type	Len	Format	Label
103	YESSpecify	Char	334	\$334.	If YES specify
104	SelectStudyForPreventionOfT1D	Char	5	\$5.	Has the participant ever participated in an observational or prevention study for T1D If Yes select studystudies
105	TestingPlaceForAutoAntibodyOut	Char	5	\$5.	Participant get autoantibody testing outside Trialnet
106	IsHeightMeasured	Num	8		Is height self measured
107	IsHeightSelfReported	Num	8		Is height self reported
108	IsWeightMeasured	Num	8		Is weight measured
109	IsWeightSelfReported	Num	8		Is weight self reported
110	DateSignedInformedConsentFormM	Char	3	\$3.	Date participant signed the Monitoring Informed Consent Form Month 2017
111	DateSignedInformedConsentFormD	Num	8		Date participant signed the Monitoring Informed Consent Form day 2017
112	DateSignedInformedConsentFormY	Num	8		Date participant signed the Monitoring Informed Consent Form Year 2017
113	DateSignedNEWInformedConsentFo	Num	8		Date signed NEW informed consent form Day
114	DateSignedNEWInformedConsentFo2	Char	3	\$3.	Date signed NEW informed consent form Month
115	DateSignedNEWInformedConsentFo3	Num	8		Date signed NEW informed consent form Year
116	MechanisticSampleCollectionDay	Num	8		Mechanistic sample collection day
117	MechanisticSampleCollectionMon	Char	3	\$3.	Mechanistic sample collection month
118	MechanisticSampleCollectionYea	Num	8		Mechanistic sample collection year
119	ParticipantAutoantibodyTesting	Num	8		Where did the participant get autoantibody testing outside of TrialNet
120	ProtocolVersion	Num	8		Protocol Version
121	SamplesCollectionDay	Num	8		Samples collection day
122	SamplesCollectionMonth	Char	3	\$3.	Samples collection Month
123	SamplesCollectionYear	Num	8		Samples collection Year
124	SeatedHeartRate	Num	8		Collect the following assessments Seated heart rate
125	SeatedRespiratoryRate	Num	8		Collect the following assessments Seated respiratory rate
126	shipspecimencollectionkit	Char	3	\$3.	Would you like the TrialNet Coordinating Center to ship an autoantibody specimen collection kit to the participant
127	Specimencollectionkitshipmentd	Char	10	\$10.	Specimen collection kit shipment date
128	Spring2019ConsentDateMonth	Char	3	\$3.	Consent Date 2019 Protocol Version Month
129	HeightNotDone	Num	8		Height Not Done
130	WeightNotDone	Num	8		Weight Not Done
131	Spring2019ConsentDateDay	Num	8		Consent Date 2019 Protocol Version Day
132	Spring2019ConsentDateYear	Num	8		Consent Date 2019 Protocol Version Year

Data Set Name: tn01_nh05c_followupriskassess.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	ParticipantDiagnosedWithT1D	Char	2		Has the participant been diagnosed with type 1 diabetes (T1D)
5	ParticipantPregnant	Char	14		Is the participant knowingly pregnant
6	ParticipantUsedInsulinOrOtherG	Char	2		Has the participant ever previously used or is currently using medications for the control of hyperglycemia
7	hyperglycemia	Char	3		Hyperglycemia
8	SignedMonitoringConsentProtoco	Char	3		Did the participant previously sign a monitoring consent form for protocol version 15Aug11
9	DateSignedNEWInformedConsentFo	Num	8		Date participant signed the informed consent form
10	DateSignedNEWInformedConsentFo2	Char	3		Date participant signed the informed consent form
11	DateSignedNEWInformedConsentFo3	Num	8		Date participant signed the informed consent form
12	InflammatoryBowelDiseaseWithin	Char	2		Inflammatory Bowel Disease Within 6 Months
13	ColitisOrColonProblemsWithinLa	Char	3		Colitis Or Colon Problems Within Last 6 Months
14	CongenitalHeartDiseaseWithinLa	Char	2		Congenital Heart Disease Within Last 6 Months
15	EpilepsyConvulsionsSeizuresWit	Char	3		Epilepsy Convulsions Seizures Within Last 6 Months
16	HepatitisOrLiverDiseaseWithinL	Char	2		Hepatitis Or Liver Disease Within Last 6 Months
17	InfectiousMononucleosisWithinL	Char	3		Infectious Mononucleosis Within Last 6 Months
18	OtherAutoimmuneDiseasesWithinL	Char	3		Other Autoimmune Diseases Within Last 6 Months
19	OtherAutoimmuneDiseasesSpecify	Char	24		Has the participant been told by a physician that they he/she has other autoimmune diseases specify
20	AddisonsDiseaseWithinLast6Months	Char	2		Addisons Disease Within Last 6 Months
21	AllergiesWithinLast6Months	Char	3		Allergies Within Last 6 Months
22	AlopeciaWithinLast6Months	Char	3		Alopecia Within Last 6 Months
23	AsthmaWithinLast6Months	Char	3		Asthma Within Last 6 Months
24	CancerWithinLast6Months	Char	2		Cancer Within Last 6 Months
25	CeliacDiseaseWithinLast6Months	Char	3		Celiac Disease Within Last 6 Months
26	PsoriasisWithinLast6Months	Char	3		Psoriasis Within Last 6 Months
27	RheumatologicWithinLast6Months	Char	2		Rheumatologic Within Last 6 Months
28	ThyroidDiseaseWithinLast6Months	Char	3		Thyroid Disease Within Last 6 Months
29	VitiligoWithinLast6Months	Char	2		Vitiligo Within Last 6 Months
30	UlcerWithinLast6Months	Char	2		Ulcer Within Last 6 Months
31	MultipleSclerosisWithinLast6Mo	Char	2		Multiple Sclerosis Within Last 6 Months
32	HighBPwithinLast6Months	Char	2		High BP Within Last 6 Months
33	PerniciousAnemiaWithinLast6Mo	Char	2		Pernicious Anemia Within Last 6 Month
34	HighCholestrolWithinLast6Months	Char	3		High Cholestrol Within Last 6 Months
35	Corticosteroids	Char	3		Is the participant taking corticosteroids
36	SteroidsSpecify	Char	50		Is the participant taking steroids specify

Num	Variable	Type	Len	Format	Label
37	ImmunosuppressiveTherapies	Char	3		Is the participant taking immunosuppressive therapies
38	ImmunosuppressiveTherapiesSpec	Char	20		Is the participant taking immunosuppressive therapies specify
39	AlphaGlucosidaseInhibitors	Char	2		Is the participant taking alpha glucosidase inhibitors
40	BetaBlockers	Char	2		Is the participant taking beta blockers
41	BetaBlockersSpecify	Char	1		Is the participant taking beta blockers specify
42	Diphenylhydantoin	Char	2		Is the participant taking diphenylhydantoin
43	Meglinitides	Char	2		Is the participant taking meglinitides
44	Metformin	Char	2		Is the participant taking metformin
45	Niacin	Char	2		Is the participant taking niacin
46	OtherGlucoseLoweringAgents	Char	2		Is the participant taking other glucose lowering agents
47	PotassiumDepletingDiurectics	Char	2		Is the participant taking potassium depleting diuretics
48	PotassiumDepletingDiurecticsSp	Char	1		Is the participant taking potassium depleting diuretics specify
49	Thiazolidinediones	Char	2		Is the participant taking thiazolidinediones
50	SeatedArmBPSystolic	Num	8		Seated arm blood pressure systolic
51	SeatedArmBPDiastolic	Num	8		Seated arm blood pressure diastolic
52	Weightkg	Num	8		Weight in kilograms
53	Weightlbs	Num	8		Weight in pounds
54	Weight	Char	13		Weight reported or measured
55	Heightcm	Num	8		Height in centimeters
56	Heightin	Num	8		Height in inches
57	SeatedHeartRate	Num	8		Seated heart rate
58	SeatedRespiratoryRate	Num	8		Seated respiratory rate
59	AntibodySampleCollected	Char	3		Antibody sample collected
60	Antibodycomment	Char	1		Antibody comment
61	BllodForDNASampleCollected	Char	3		Blood for DNA sample collected
62	BllodForDNAComment	Char	36		Blood for DNA comment
63	BloodForCellsSampleCollected	Char	3		Blood for cells sample collected
64	BloodForCellsComment	Char	51		Blood for cells comment
65	BloodForRNASampleCollected	Char	3		Blood for RNA sample collected
66	BloodForRNAComment	Char	51		Blood for RNA comment
67	HbA1cSamplesCollected	Char	3		HbA1c sample collected
68	HbA1cComment	Char	13		HbA1c comment
69	OGTTSampleCollected	Char	3		OGTT Sample Collected
70	OGTTComment	Char	184		OGTT Comment
71	PlasmaSampleCollected	Char	3		Plasma Sample Collected
72	PlasmaComment	Char	51		Plasma Sample comment
73	SerumForProteomicsSampleCollec	Char	3		Sample collected for serum proteomics
74	SerumForProteomicsComment	Char	51		Serum for proteomics comment
75	SerumMechanisticSerumSampleCol	Char	3		Sample collected for serum mechanistic

Num	Variable	Type	Len	Format	Label
76	SerumMechanisticSerumComment	Char	1		Serum mechanistic comment
77	WholeBloodPBMCPlasmaSampleColl	Char	3		Sample collected for whole blood PBMC plasma
78	WholeBloodPBMCPlasmaComment	Char	25		Whole Blood PBMC Plasma Comment
79	ConsentToContinuedStorageOfBlo	Char	3		Did the participant consent to continued storage of
80	IsParticipantPregnant	Char	14		Is the participant pregnant planning to become pregnant
81	LimitedLifeExpectancyOrImmunos	Char	2		Limited Life Expectancy or immunosuppressive or immunomodulatory therapies
82	immunomodulatory	Char	2		immunomodulatory
83	participantdiagnosedT1D	Char	3		Has the participant been diagnosed with type 1 diabetes (T1D)
84	systemicsteroids	Char	2		systemic steroids
85	YESSpecify	Char	45		YES Specify
86	MechanisticSampleCollectionDay	Num	8		Mechanistic Sample Collection Day
87	MechanisticSampleCollectionMon	Char	3		Mechanistic Sample Collection Mon
88	MechanisticSampleCollectionYea	Num	8		Mechanistic Sample Collection Yea
89	ProtocolVersion	Num	8		Protocol Version
90	SamplesCollectionDay	Num	8		Samples Collection Day
91	SamplesCollectionMonth	Char	3		Samples Collection Month
92	SamplesCollectionYear	Num	8		Samples Collection Year
93	Height	Char	13		Height

Data Set Name: tn01_nh05_followupriskassess.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	Visit_Type	Char	16		Visit Type
5	ParticipantDiagnosedWithT1D	Char	3		Has the participant been diagnosed with type 1 diabetes (T1D)
6	ParticipantUsedInsulinOrOtherG	Char	3		Has the participant ever previously used or is currently using medications for the control of hyperglycemia
7	LimitedLifeExpectancyOrImmunos	Char	3		Limited Life Expectancy or immunosuppressive or immunomodulatory therapies
8	ParticipantPregnant	Char	14		Is the participant knowingly pregnant
9	AsthmaWithinLast6Months	Char	3		Asthma Within Last 6 Months
10	CeliacDiseaseWithinLast6Months	Char	3		Celiac Disease Within Last 6 Months
11	InflammatoryBowelDiseaseWithin	Char	3		Inflammatory Bowel Disease Within 6 Months
12	AddisonsDiseaseWithinLast6Months	Char	3		Addisons Disease Within Last 6 Months
13	VitiligoWithinLast6Months	Char	3		Vitiligo Within Last 6 Months
14	ThyroidDiseaseWithinLast6Months	Char	3		Thyroid Disease Within Last 6 Months
15	PsoriasisWithinLast6Months	Char	3		Psoriasis Within Last 6 Months
16	AlopeciaWithinLast6Months	Char	3		Alopecia Within Last 6 Months
17	RheumatologicWithinLast6Months	Char	3		Rheumatologic Within Last 6 Months
18	ColitisOrColonProblemsWithinLa	Char	3		Colitis Or Colon Problems Within Last 6 Months
19	CongenitalHeartDiseaseWithinLa	Char	3		Congenital Heart Disease Within Last 6 Months
20	EpilepsyConvulsionsSeizuresWit	Char	3		Epilepsy Convulsions Seizures Within Last 6 Months
21	HepatitisOrLiverDiseaseWithinL	Char	3		Hepatitis Or Liver Disease Within Last 6 Months
22	InfectiousMononucleosisWithinL	Char	3		Infectious Mononucleosis Within Last 6 Months
23	OtherAutoimmuneDiseasesWithinL	Char	3		Other Autoimmune Diseases Within Last 6 Months
24	AllergiesWithinLast6Months	Char	3		Allergies Within Last 6 Months
25	CancerWithinLast6Months	Char	3		Cancer Within Last 6 Months
26	UlcerWithinLast6Months	Char	3		Ulcer Within Last 6 Months
27	HighBPwithinLast6Months	Char	3		High BP Within Last 6 Months
28	PerniciousAnemiaWithinLast6Mo	Char	3		Pernicious Anemia Within Last 6 Month
29	MultipleSclerosisWithinLast6Mo	Char	3		Multiple Sclerosis Within Last 6 Months
30	OtherAutoimmuneDiseasesSpecify	Char	73		Has the participant been told by a physician that they he/she has other autoimmune diseases specify
31	hyperglycemia	Char	3		Hyperglycemia
32	immunomodulatory	Char	3		immunomodulatory
33	Corticosteroids	Char	3		Is the participant taking corticosteroids
34	YESSpecify	Char	303		YES Specify
35	ImmunosuppressiveTherapies	Char	3		Is the participant taking immunosuppressive therapies
36	ImmunosuppressiveTherapiesSpec	Char	25		Is the participant taking immunosuppressive therapies specify

Num	Variable	Type	Len	Format	Label
37	BetaBlockers	Char	3		Is the participant taking beta blockers
38	BetaBlockersSpecify	Char	27		Is the participant taking beta blockers specify
39	PotassiumDepletingDiurectics	Char	3		Is the participant taking potassium depleting diuretics
40	PotassiumDepletingDiurecticsSp	Char	53		Is the participant taking potassium depleting diuretics specify
41	systemicsteroids	Char	3		systemic steroids
42	SteroidsSpecify	Char	190		Is the participant taking steroids specify
43	Diphenylhydantoin	Char	3		Is the participant taking diphenylhydantoin
44	Metformin	Char	3		Is the participant taking metformin
45	Niacin	Char	3		Is the participant taking niacin
46	Thiazolidinediones	Char	3		Is the participant taking thiazolidinediones
47	AlphaGlucosidaseInhibitors	Char	3		Is the participant taking alpha glucosidase inhibitors
48	OtherGlucoseLoweringAgents	Char	3		Is the participant taking other glucose lowering agents
49	SeatedArmBPSystolic	Num	8		Seated arm blood pressure systolic
50	SeatedArmBPDiastolic	Num	8		Seated arm blood pressure diastolic
51	Weight	Char	13		Weight reported or measured
52	Weightkg	Num	8		Weight in kilograms
53	Weightlbs	Num	8		Weight in pounds
54	WeightNotDone	Num	8		Weight Not Done
55	Height	Char	13		Height
56	Heightcm	Num	8		Height in centimeters
57	Heightin	Num	8		Height in inches
58	HeightNotDone	Num	8		Height Not Done
59	SeatedHeartRate	Num	8		Seated heart rate
60	SeatedRespiratoryRate	Num	8		Seated respiratory rate
61	AntibodySampleCollected	Char	3		Antibody sample collected
62	Antibodycomment	Char	132		Antibody comment
63	BlloodForDNASampleCollected	Char	3		Blood for DNA sample collected
64	BlloodForDNAComment	Char	120		Blood for DNA comment
65	BloodForCellsSampleCollected	Char	3		Blood for cells sample collected
66	BloodForCellsComment	Char	144		Blood for cells comment
67	HbA1cSamplesCollected	Char	3		HbA1c sample collected
68	HbA1cComment	Char	147		HbA1c comment
69	OGTTSampleCollected	Char	3		OGTT Sample Collected
70	OGTTComment	Char	129		OGTT Comment
71	PlasmaSampleCollected	Char	3		Plasma Sample Collected
72	PlasmaComment	Char	120		Plasma Sample comment
73	BloodForRNASampleCollected	Char	3		Blood for RNA sample collected
74	BloodForRNAComment	Char	158		Blood for RNA comment
75	SerumForProteomicsSampleCollec	Char	3		Sample collected for serum proteomics

Num	Variable	Type	Len	Format	Label
76	SerumForProteomicsComment	Char	120		Serum for proteomics comment
77	SerumMechanisticSerumSampleCol	Char	3		Sample collected for serum mechanistic
78	SerumMechanisticSerumComment	Char	34		Serum mechanistic comment
79	MechanisticSampleCollectionDay	Num	8		Mechanistic Sample Collection Day
80	MechanisticSampleCollectionMon	Char	3		Mechanistic Sample Collection Mon
81	MechanisticSampleCollectionYea	Num	8		Mechanistic Sample Collection Yea
82	WholeBloodPBMCPlasmaSampleColl	Char	3		Sample collected for whole blood PBMC plasma
83	WholeBloodPBMCPlasmaComment	Char	83		Whole Blood PBMC Plasma Comment
84	SamplesCollectionDay	Num	8		Samples Collection Day
85	SamplesCollectionMonth	Char	3		Samples Collection Month
86	SamplesCollectionYear	Num	8		Samples Collection Year
87	shippedspecimencollectionkit	Char	3		Would you like the TrialNet Coordinating Center to ship an autoantibody specimen collection kit to the participant
88	Specimencollectionkitshipmentd	Char	10		Specimen collection kit shipment date
89	PermissionForSampleStorage	Char	3		Storage of his/her samples for future testing
90	DateSignedNEWInformedConsentFo	Num	8		Date participant signed the informed consent form
91	DateSignedNEWInformedConsentFo2	Char	3		Date participant signed the informed consent form
92	DateSignedNEWInformedConsentFo3	Num	8		Date participant signed the informed consent form
93	ProtocolVersion	Num	8		Protocol Version
94	participantdiagnosedT1D	Char	3		Has the participant been diagnosed with type 1 diabetes (T1D)
95	IsParticipantPregnant	Char	14		Is the participant pregnant planning to become pregnant
96	SignedMonitoringConsentProtoco	Char	3		Did the participant previously sign a monitoring consent form for protocol version 15Aug11
97	ConsenToContinuedStorageOfBloo	Char	14		Did the participant consent to continued storage of
98	DateConsentSignedDay	Num	8		Date consent signed day
99	DateConsentSignedMonth	Char	3		Date consent signed month
100	DateConsentSignedYear	Num	8		Date consent signed year
101	HighCholesterolWithinLast6Months	Char	3		High Cholesterol Within Last 6 Months
102	Meglitinides	Char	3		Is the participant taking Meglitinides

Data Set Name: tn01_nh07_changeofstatus.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	DateCompletionDD	Num	8		Date form completed day
5	DateCompletionMM	Char	3	\$3.	Date form completed month
6	DateCompletionYYYY	Num	8		Date form completed year
7	DateStatusChangeDay	Num	8		Date change in status became effective Day
8	DateStatusChangeMonth	Char	3	\$3.	Date change in status became effective Month
9	DateStatusChangeYear	Num	8		Date change in status became effective Year
10	DoRDay	Num	8		Date of reactivation Day
11	DoRMonth	Char	3	\$3.	Date of reactivation Month
12	DoRYear	Num	8		Date of reactivation Year
13	ChangeOfStatusOccuring	Char	98	\$98.	Change in status that has occurred
14	DoWDay	Num	8		Date of withdrawal Day
15	DoWMonth	Char	3	\$3.	Date of withdrawal Month
16	DoWYear	Num	8		Date of withdrawal Year
17	ReasonForWithdrawal	Char	45	\$45.	Record the primary reason for withdrawal
18	IsParticipantWillingBeContacte	Char	7	\$7.	Is the participant still willing to be contacted
19	ParticipantCompletedEntireStud	Char	3	\$3.	Participant completed entire study
20	WillingToBeContacted	Char	3	\$3.	Is the subject still willing to be contacted
21	WillingToContinueAfterPregnanc	Char	3	\$3.	Is the participant willing to continue participation as a Control after completion of pregnancy
22	WithdrewConsentWhy	Char	68	\$68.	If withdrew consent selected record the reason why
23	ReasonAdverseEventSpecify	Char	106	\$106.	Adverse event reason specify
24	ReasonForWithdrawalOTHER	Char	789	\$789.	If other withdrawal reason specify
25	ReasonWithdrewConsentSpecify	Char	770	\$770.	Specify reason for withdrawing consent
26	WithdrewConsentWhyIfOther	Char	189	\$189.	If withdrew consent selected record the reason why other selected specify
27	LastAttendedVisitMonth	Char	3	\$3.	If other selected specify date of visit month
28	PregnancyCompletionMonth	Char	3	\$3.	If pregnant what is the estimated date of completion of pregnancy month
29	PregnancyCompletionDay	Num	8		If pregnant what is the estimated date of completion of pregnancy day
30	PregnancyCompletionYear	Num	8		If pregnant what is the estimated date of completion of pregnancy year
31	LastAttendedVisitDay	Num	8		If other selected specify date of visit day
32	LastAttendedVisitYear	Num	8		If other selected specify date of visit year
33	PhiX174VisitNumber	Num	8		Record week number if PhiX174 visit only
34	ParticipantWillingToBeContacte	Char	7	\$7.	Is the participant still willing to be contacted
35	WithdrewConsentReason	Char	95	\$95.	If withdrew consent selected record the reason why
36	primaryreasonforreactivation	Char	73	\$73.	Record the primary reason for reactivation select one
37	SubjecthistoryTriggeredChangeo	Char	7	\$7.	Which Subject history Triggered Change of status

Num	Variable	Type	Len	Format	Label
38	ProtocolVersion	Num	8		ProtocolVersion
39	ReasonForWithdrawalAdverseEven	Num	8		Adverse Event ID

Data Set Name: tn01_nh08_diabetesonset_old.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	DiagnosisDay	Num	8		Diagnosis day
5	DiagnosisMonth	Char	3	\$3.	Diagnosis month
6	DiagnosisYear	Num	8		Diagnosis year
7	DiagnosisBy	Char	19	\$19.	Diagnosis made by
8	DiagnosisByOthersSpecify	Char	97	\$97.	If other facility specify
9	InsulinTreatmentStartedDay	Num	8		Day insulin treatment started
10	InsulinTreatmentStartedMonth	Char	3	\$3.	Month insulin treatment started
11	InsulinTreatmentStartedYear	Num	8		Year insulin treatment started
12	DateInsulinTreatmentStartedUnk	Num	8		Date Insulin treatment started Unknown
13	HospitalizedAtDiagnosisTime	Char	3	\$3.	Was the participant hospitalized at the time of diagnosis
14	HospitalizedAtDiagnosisTime23	Char	1	\$1.	Was the participant hospitalized at the time of diagnosis
15	AdmissionDay	Num	8		Day of admission
16	AdmissionMonth	Char	3	\$3.	Month of admission
17	AdmissionYear	Num	8		Year of admission
18	DischargeDay	Num	8		Day of discharge
19	DischargeMonth	Char	3	\$3.	Month of discharge
20	DischargeYear	Num	8		Year of discharge
21	Polyuria	Char	3	\$3.	Did the participant experience Polyuria
22	Polyuria23	Char	1	\$1.	Did the participant experience Polyuria
23	PolyuriaMonth	Char	3	\$3.	Month polyuria experienced
24	PolyuriaYear	Num	8		Year polyuria experienced
25	Polydipsia	Char	3	\$3.	Did the participant experience Polydipsia
26	Polydipsia23	Char	1	\$1.	Did the participant experience Polydipsia
27	PolydipsiaMonth	Char	3	\$3.	Month polydipsia experienced
28	PolydipsiaYear	Num	8		Year polydipsia experienced
29	Polyphagia	Char	3	\$3.	Did the participant experience Polyphagia
30	Polyphagia23	Char	1	\$1.	Did the participant experience Polyphagia
31	PolyphagiaMonth	Char	3	\$3.	Month polyphagia experienced
32	PolyphagiaYear	Num	8		Year polyphagia experienced
33	Fatigue	Char	3	\$3.	Did the participant experience fatigue
34	Fatigue23	Char	1	\$1.	Did the participant experience fatigue
35	FatigueMonth	Char	3	\$3.	Month fatigue experienced
36	FatigueYear	Num	8		Year fatigue experienced
37	UnexplainedWeightLoss	Char	3		Did the participant experience unexplained weight loss

Num	Variable	Type	Len	Format	Label
38	UnexplainedWeightLoss23	Char	1		Did the participant experience unexplained weight loss
39	UnexplainedWeightLossMonth	Char	3		Month of unexplained weight loss
40	UnexplainedWeightLossYear	Num	8		Year of unexplained weight loss
41	WeightLostInKgs	Num	8		Amount of weight loss in kgs
42	WeightLostInLbs	Num	8		Amount of weight loss in lbs
43	Ketoacidosis	Char	3	\$3.	Did the participant experience ketoacidosis
44	Ketoacidosis23	Char	1	\$1.	Did the participant experience Ketoacidosis
45	KetoacidosisMonth23	Char	3	\$3.	Did the participant experience Ketoacidosismonth
46	KetoacidosisYear23	Num	8		Did the participant experience Ketoacidosisyear
47	PlasmaGlucoseResult	Num	8		Plasma glucose result
48	PlasmaGlucoseUnits	Char	6	\$6.	Plasma glucose units
49	PlasmaGlucoseRefRangeLow	Num	8		Plasma glucose low reference range
50	PlasmaGlucoseRefRangeHigh	Num	8		Plasma glucose high reference range
51	PlasmaGlucoseday	Num	8		Plasma glucose day
52	PlasmaGlucoseMonth	Char	3	\$3.	Plasma glucose month
53	PlasmaGlucoseYear	Num	8		Plasma glucose year
54	pHResult	Num	8		pH(serum) result
55	pHUnits	Char	7	\$7.	pH(serum) units
56	pHReferenceRangeLow	Num	8		pH(serum) low reference range
57	pHReferenceRangeHigh	Num	8		pH(serum) high reference range
58	pHday	Num	8		pH(serum) day
59	pHMonth	Char	3	\$3.	pH(serum) month
60	pHYear	Num	8		pH(serum) year
61	SerumKetonesResult	Num	8		Serum ketones result
62	SerumKetonesUnits	Char	7	\$7.	Serum ketones units
63	SerumKetonesRefRangeLow	Num	8		Serum ketones low reference range
64	SerumKetonesRefRangeHigh	Num	8		Serum ketones high reference range
65	SerumKetonesday	Num	8		Serum ketones day
66	SerumKetonesMonth	Char	3	\$3.	Serum ketones month
67	SerumKetonesYear	Num	8		Serum ketones year
68	AnionGapResult	Num	8		Anion gap result
69	AnionGapUnits	Char	22	\$22.	Anion gap units
70	AnionGapRefRangeLow	Num	8		Anion gap low reference range
71	AnionGapRefRangeHigh	Num	8		Anion gap high reference range
72	AnionGapDay	Num	8		Anion gap day
73	AnionGapMonth	Char	3	\$3.	Anion gap month
74	AnionGapYear	Num	8		Anion gap year
75	BicarbonateResult	Num	8		Bicarbonate result
76	BicarbonateUnits	Char	22	\$22.	Bicarbonate units

Num	Variable	Type	Len	Format	Label
77	BicarbonateRefRangeLow	Num	8		Bicarbonate low reference range
78	BicarbonateRefRangeHigh	Num	8		Bicarbonate high reference range
79	BicarbonateDay	Num	8		bicarbonate day
80	BicarbonateMonth	Char	3	\$3.	Bicarbonate month
81	BicarbonateYear	Num	8		Bicarbonate year
82	UrineKetonesResult	Num	8		Urine ketones result
83	UrineKetonesUnits	Char	7	\$7.	Urine ketones units
84	UrineKetonesRefRangeLow	Num	8		Urine ketones low reference range
85	UrineKetonesRefRangeHigh	Num	8		Urine ketones high reference range
86	UrineKetonesDay	Num	8		Urine ketones day
87	UrineKetonesMonth	Char	3	\$3.	Urine ketones month
88	UrineKetonesYear	Num	8		Urine ketones year
89	Result1_1	Num	8		Glucose level result
90	Units1_1	Char	6	\$6.	Glucose level units
91	LowerReferenceRange1_1	Num	8		Glucose level low reference range
92	HigherReferenceRange1_1	Num	8		Glucose level high reference range
93	GlucoseDay1_1	Num	8		Glucose day
94	GlucoseMonth1_1	Char	3	\$3.	Glucose month
95	GlucoseYear1_1	Num	8		Glucose year
96	GlucoseType1_1	Char	9	\$9.	Glucose type
97	MeasuredBy1_1	Char	9	\$9.	Glucose levels measured by
98	Result2_1	Num	8		Glucose level result
99	Units2_1	Char	6	\$6.	Glucose level units
100	LowerReferenceRange2_1	Num	8		Glucose level low reference range
101	HigherReferenceRange2_1	Num	8		Glucose level high reference range
102	GlucoseDay2_1	Num	8		Glucose day
103	GlucoseMonth2_1	Char	3	\$3.	Glucose month
104	GlucoseYear2_1	Num	8		Glucose year
105	GlucoseType2_1	Char	9	\$9.	Glucose type
106	MeasuredBy2_1	Char	9	\$9.	Glucose levels measured by
107	Result3_1	Num	8		Glucose level result
108	Units3_1	Char	6	\$6.	Glucose level units
109	LowerReferenceRange3_1	Num	8		Glucose level lower reference range
110	HigherReferenceRange3_1	Num	8		Glucose level higher reference range
111	GlucoseDay3_1	Num	8		Glucose day
112	GlucoseMonth3_1	Char	3	\$3.	Glucose month
113	GlucoseYear3_1	Num	8		Glucose year
114	GlucoseType3_1	Char	9	\$9.	Glucose type
115	MeasuredBy3_1	Char	9	\$9.	Glucose levels measured by

Num	Variable	Type	Len	Format	Label
116	Result4_1	Num	8		Glucose level result
117	Units4_1	Char	6	\$6.	Glucose level units
118	LowerReferenceRange4_1	Num	8		Glucose level low reference range
119	HigherReferenceRange4_1	Num	8		Glucose level high reference range
120	GlucoseDay4_1	Num	8		Glucose day
121	GlucoseMonth4_1	Char	3	\$3.	Glucose month
122	GlucoseYear4_1	Num	8		Glucose year
123	GlucoseType4_1	Char	9	\$9.	Glucose type
124	MeasuredBy4_1	Char	9	\$9.	Glucose levels measured by
125	Result5_1	Num	8		Glucose level result
126	Units5_1	Char	6	\$6.	Glucose level units
127	LowerReferenceRange5_1	Num	8		Glucose level low reference range
128	HigherReferenceRange5_1	Num	8		Glucose level high reference range
129	GlucoseDay5_1	Num	8		Glucose day
130	GlucoseMonth5_1	Char	3	\$3.	Glucose month
131	GlucoseYear5_1	Num	8		Glucose year
132	GlucoseType5_1	Char	9	\$9.	Glucose type
133	MeasuredBy5_1	Char	9	\$9.	Glucose levels measured by
134	Result6_1	Num	8		Glucose level result
135	Units6_1	Char	6	\$6.	Glucose level units
136	LowerReferenceRange6_1	Num	8		Glucose level low reference range
137	HigherReferenceRange6_1	Num	8		Glucose level high reference range
138	GlucoseDay6_1	Num	8		Glucose day
139	GlucoseMonth6_1	Char	3	\$3.	Glucose month
140	GlucoseYear6_1	Num	8		Glucose year
141	GlucoseType6_1	Char	9	\$9.	Glucose type
142	MeasuredBy6_1	Char	9	\$9.	Glucose levels measured by
143	Result7_1	Num	8		Glucose level result
144	Units7_1	Char	6	\$6.	Glucose level units
145	LowerReferenceRange7_1	Num	8		Glucose level low reference range
146	HigherReferenceRange7_1	Num	8		Glucose level high reference range
147	GlucoseDay7_1	Num	8		Glucose day
148	GlucoseMonth7_1	Char	3	\$3.	Glucose month
149	GlucoseYear7_1	Num	8		Glucose year
150	GlucoseType7_1	Char	9	\$9.	Glucose type
151	MeasuredBy7_1	Char	9	\$9.	Glucose levels measured by
152	Result8_1	Num	8		Glucose level result
153	Units8_1	Char	6	\$6.	Glucose level units
154	LowerReferenceRange8_1	Num	8		Glucose level low reference range

Num	Variable	Type	Len	Format	Label
155	HigherReferenceRange8_1	Num	8		Glucose level high reference range
156	GlucoseDay8_1	Num	8		Glucose day
157	GlucoseMonth8_1	Char	3	\$3.	Glucose month
158	GlucoseYear8_1	Num	8		Glucose year
159	GlucoseType8_1	Char	7	\$7.	Glucose type
160	MeasuredBy8_1	Char	9	\$9.	Glucose levels measured by
161	Result9_1	Num	8		Glucose level result
162	Units9_1	Char	6	\$6.	Glucose level units
163	LowerReferenceRange9_1	Num	8		Glucose level low reference range
164	HigherReferenceRange9_1	Num	8		Glucose level high reference range
165	GlucoseDay9_1	Num	8		Glucose day
166	GlucoseMonth9_1	Char	3	\$3.	Glucose month
167	GlucoseYear9_1	Num	8		Glucose year
168	GlucoseType9_1	Char	6	\$6.	Glucose type
169	MeasuredBy9_1	Char	9	\$9.	Glucose levels measured by
170	Result10_1	Num	8		Glucose level result
171	Units10_1	Char	6	\$6.	Glucose level units
172	LowerReferenceRange10_1	Num	8		Glucose level low reference range
173	HigherReferenceRange10_1	Num	8		Glucose level high reference range
174	GlucoseDay10_1	Num	8		Glucose day
175	GlucoseMonth10_1	Char	3	\$3.	Glucose month
176	GlucoseYear10_1	Num	8		Glucose year
177	GlucoseType10_1	Char	7	\$7.	Glucose type
178	MeasuredBy10_1	Char	9	\$9.	Glucose levels measured by
179	Result11_1	Num	8		Glucose level result
180	Units11_1	Char	6	\$6.	Glucose level units
181	LowerReferenceRange11_1	Num	8		Glucose level low reference range
182	HigherReferenceRange11_1	Num	8		Glucose level high reference range
183	GlucoseDay11_1	Num	8		Glucose day
184	GlucoseMonth11_1	Char	3	\$3.	Glucose month
185	GlucoseYear11_1	Num	8		Glucose year
186	GlucoseType11_1	Char	6	\$6.	Glucose type
187	MeasuredBy11_1	Char	9	\$9.	Glucose levels measured by
188	Result12_1	Num	8		Glucose level result
189	Units12_1	Char	1	\$1.	Glucose level units
190	LowerReferenceRange12_1	Num	8		Glucose level low reference range
191	HigherReferenceRange12_1	Num	8		Glucose level high reference range
192	GlucoseDay12_1	Num	8		Glucose day
193	GlucoseMonth12_1	Char	3	\$3.	Glucose month

Num	Variable	Type	Len	Format	Label
194	GlucoseYear12_1	Num	8		Glucose year
195	GlucoseType12_1	Char	6	\$6.	Glucose type
196	MeasuredBy12_1	Char	9	\$9.	Glucose levels measured by
197	HbA1cResult	Num	8		Other laboratory values hba1c result
198	HbA1cLowerReferenceRange	Num	8		Other laboratory values hba1c low reference range
199	HbA1chigherrReferenceRange	Num	8		Other laboratory values hba1c high reference range
200	HbA1cDay	Num	8		Other laboratory values hba1c day
201	HbA1cMonth	Char	3	\$3.	Other laboratory values hba1c month
202	HbA1cYear	Num	8		Other laboratory values hba1c year
203	Currentvisitorlastscheduledvis	Char	8	\$8.	Current visit or last scheduled visit preceding diagnosis of diabetes

Data Set Name: tn01_nh08_diabonset_current.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	CriteriaParticipantDiagnosewit	Char	185	\$185.	1Select ONE set of criteria by which the participant was diagnosed with type 1 diabetes
5	D1FastingPlasmaGlucDD1_1	Num	8		D1 Fasting Plasma Glucose DD
6	D1FastingPlasmaGlucMM1_1	Char	3	\$3.	D1 Fasting Plasma Glucose MM
7	D1FastingPlasmaGlucYYYY1_1	Num	8		D1 Fasting Plasma Glucose YYYY
8	D1FastingPlasmaGlucResult1_1	Num	8		D1 Fasting Plasma Glucose Result
9	D1FastingPlasmaGlucUnits1_1	Char	6	\$6.	D1 Fasting Plasma Glucose Units
10	D1FastingPlasmaGlucDD2_1	Num	8		D1 Fasting Plasma Glucose DD
11	D1FastingPlasmaGlucMM2_1	Char	3	\$3.	D1 Fasting Plasma Glucose MM
12	D1FastingPlasmaGlucYYYY2_1	Num	8		D1 Fasting Plasma Glucose YYYY
13	D1FastingPlasmaGlucResult2_1	Num	8		D1 Fasting Plasma Glucose Result
14	D1FastingPlasmaGlucUnits2_1	Char	6	\$6.	D1 Fasting Plasma Glucose Units
15	D1FastingPlasmaGlucDD3_1	Num	8		D1 Fasting Plasma Glucose DD
16	D1FastingPlasmaGlucMM3_1	Char	3	\$3.	D1 Fasting Plasma Glucose MM
17	D1FastingPlasmaGlucYYYY3_1	Num	8		D1 Fasting Plasma Glucose YYYY
18	D1FastingPlasmaGlucResult3_1	Num	8		D1 Fasting Plasma Glucose Result
19	D1FastingPlasmaGlucUnits3_1	Char	5	\$5.	D1 Fasting Plasma Glucose Units
20	D2aOGTTFastingGlucDD1_1	Num	8		D2a OGTT Fasting Glucose DD
21	D2aOGTTFastingGlucMM1_1	Char	3		D2a OGTT Fasting Glucose MM
22	D2aOGTTFastingGlucYYYY1_1	Num	8		D2a OGTT Fasting Glucose YYYY
23	D2aOGTTFastingGlucResult1_1	Num	8		D2a OGTT Fasting Glucose Result
24	D2aOGTTFastingGlucUnits1_1	Char	6		D2a OGTT Fasting Glucose Units
25	D2aOGTTFastingGlucDD2_1	Num	8		D2a OGTT Fasting Glucose DD
26	D2aOGTTFastingGlucMM2_1	Char	3		D2a OGTT Fasting Glucose MM
27	D2aOGTTFastingGlucYYYY2_1	Num	8		D2a OGTT Fasting Glucose YYYY
28	D2aOGTTFastingGlucResult2_1	Num	8		D2a OGTT Fasting Glucose Result
29	D2aOGTTFastingGlucUnits2_1	Char	6		D2a OGTT Fasting Glucose Units
30	D2b2HourGlucUnits2_1	Char	6	\$6.	D2b 2 hour Glucose Units
31	D2b2HourGlucDD1_1	Num	8		D2b 2 hour Glucose DD
32	D2b2HourGlucMM1_1	Char	3	\$3.	D2b 2 hour Glucose MM
33	D2b2HourGlucYYYY1_1	Num	8		D2b 2 hour Glucose YYYY
34	D2b2HourGlucResult1_1	Num	8		D2b 2 hour Glucose Result
35	D2b2HourGlucUnits1_1	Char	6	\$6.	D2b 2 hour Glucose Units
36	D2b2HourGlucDD2_1	Num	8		D2b 2 hour Glucose DD
37	D2b2HourGlucMM2_1	Char	3	\$3.	D2b 2 hour Glucose MM

Num	Variable	Type	Len	Format	Label
38	D2b2HourGlucYYYY2_1	Num	8		D2b 2 hour Glucose YYYY
39	D2b2HourGlucResult2_1	Num	8		D2b 2 hour Glucose Result
40	D3RandomPlasmaGlucDD1_1	Num	8		D3 Random Plasma Glucose DD
41	D3RandomPlasmaGlucMM1_1	Char	3	\$3.	D3 Random Plasma Glucose MM
42	D3RandomPlasmaGlucYYYY1_1	Num	8		D3 Random Plasma Glucose YYYY
43	D3RandomPlasmaGlucResult1_1	Num	8		D3 Random Plasma Glucose Result
44	D3RandomPlasmaGlucUnits1_1	Char	6	\$6.	D3 Random Plasma Glucose Units
45	D4HbA1cDD1_1	Num	8		D4 HbA1c DD
46	D4HbA1cMM1_1	Char	3	\$3.	D4 HbA1c MM
47	D4HbA1cYYYY1_1	Num	8		D4 HbA1cYYYY
48	D4HbA1cResult1_1	Num	8		D4 HbA1cResult
49	D4HbA1cDD2_1	Num	8		D4 HbA1cDD
50	D4HbA1cMM2_1	Char	3	\$3.	D4 HbA1cMM
51	D4HbA1cYYYY2_1	Num	8		D4 HbA1c YYYY
52	D4HbA1cResult2_1	Num	8		D4 HbA1c Result
53	D5MeterReadingLoc1_1	Char	9	\$9.	D5 Meter Reading Location
54	D5MeterReadingDD1_1	Num	8		D5 Meter Reading DD
55	D5MeterReadingMM1_1	Char	3	\$3.	D5 Meter Reading MM
56	D5MeterReadingYYYY1_1	Num	8		D5 Meter Reading YYYY
57	D5MeterReadingResult1_1	Num	8		D5 Meter Reading Result
58	D5MeterReadingUnit1_1	Char	6	\$6.	D5 Meter Reading Unit
59	D5MeterReadingLoc2_1	Char	9	\$9.	D5 Meter Reading Location
60	D5MeterReadingDD2_1	Num	8		D5 Meter Reading DD
61	D5MeterReadingMM2_1	Char	3	\$3.	D5 Meter Reading MM
62	D5MeterReadingYYYY2_1	Num	8		D5 Meter ReadingYYYY
63	D5MeterReadingResult2_1	Num	8		D5 Meter Reading Result
64	D5MeterReadingUnit2_1	Char	6	\$6.	D5 Meter Reading Unit
65	D5MeterReadingLoc3_1	Char	9	\$9.	D5 Meter Reading Location
66	D5MeterReadingDD3_1	Num	8		D5 Meter Reading DD
67	D5MeterReadingMM3_1	Char	3	\$3.	D5 Meter Reading MM
68	D5MeterReadingYYYY3_1	Num	8		D5 Meter Reading YYYY
69	D5MeterReadingResult3_1	Num	8		D5 Meter Reading Result
70	D5MeterReadingUnit3_1	Char	6	\$6.	D5 Meter Reading Unit
71	D5MeterReadingLoc4_1	Char	9	\$9.	D5 Meter Reading Location
72	D5MeterReadingDD4_1	Num	8		D5 Meter Reading DD
73	D5MeterReadingMM4_1	Char	3	\$3.	D5 Meter Reading MM
74	D5MeterReadingYYYY4_1	Num	8		D5 Meter Reading YYYY
75	D5MeterReadingResult4_1	Num	8		D5 Meter Reading Result
76	D5MeterReadingUnit4_1	Char	6	\$6.	D5 Meter Reading Unit

Num	Variable	Type	Len	Format	Label
77	D5OtherTestResultDD1_1	Num	8		D6 Other Test Result DD
78	D5OtherTestResultMM1_1	Char	3	\$3.	D6 Other Test Result MM
79	D5OtherTestResultYYYY1_1	Num	8		D6 Other Test Result YYYY
80	testName1_1	Char	30	\$30.	Test Name
81	D5OtherTestResultResult1_1	Char	16	\$16.	D6 Other Test ResultResult
82	D6OtherTestResultUnit1_1	Char	7	\$7.	D6 Other Test ResultUnit
83	D5OtherTestResultDD2_1	Num	8		D6 Other Test ResultDD
84	D5OtherTestResultMM2_1	Char	3	\$3.	D6 Other Test ResultMM
85	D5OtherTestResultYYYY2_1	Num	8		D6 Other Test ResultYYYY
86	testName2_1	Char	19	\$19.	Test Name
87	D5OtherTestResultResult2_1	Char	4	\$4.	D6 Other Test ResultResult
88	D6OtherTestResultUnit2_1	Char	6	\$6.	D6 Other Test ResultUnit
89	D5OtherTestResultDD3_1	Num	8		D6 Other Test ResultDD
90	D5OtherTestResultMM3_1	Char	3	\$3.	D6 Other Test ResultMM
91	D5OtherTestResultYYYY3_1	Num	8		D6 Other Test ResultYYYY
92	testName3_1	Char	24	\$24.	Test Name
93	D5OtherTestResultResult3_1	Char	4	\$4.	D6 Other Test ResultResult
94	D6OtherTestResultUnit3_1	Char	6	\$6.	D6 Other Test ResultUnit
95	D5OtherTestResultDD4_1	Num	8		D6 Other Test ResultDD
96	D5OtherTestResultMM4_1	Char	3	\$3.	D6 Other Test ResultMM
97	D5OtherTestResultYYYY4_1	Num	8		D6 Other Test ResultYYYY
98	testName4_1	Char	30	\$30.	Test Name
99	D5OtherTestResultResult4_1	Char	4	\$4.	D6 Other Test ResultResult
100	D6OtherTestResultUnit4_1	Char	6	\$6.	D6 Other Test ResultUnit
101	D5OtherTestResultDD5_1	Num	8		D6 Other Test ResultDD
102	D5OtherTestResultMM5_1	Char	3	\$3.	D6 Other Test ResultMM
103	D5OtherTestResultYYYY5_1	Num	8		D6 Other Test ResultYYYY
104	testName5_1	Char	14	\$14.	Test Name
105	D5OtherTestResultResult5_1	Char	4	\$4.	D6 Other Test ResultResult
106	D6OtherTestResultUnit5_1	Char	6	\$6.	D6 Other Test ResultUnit
107	E1aDKA	Char	7	\$7.	E1a DKA
108	E1aDateOfOnsetDD	Num	8		E1a Date of OnsetDD
109	E1aDateOfOnsetMM	Char	3	\$3.	E1a Date of OnsetMM
110	E1aDateofOnsetYYYY	Num	8		E1a Date of OnsetYYYY
111	E1bPolyuria	Char	7		E1b polyuria
112	E1bDateOfOnsetDD	Num	8		E1b Date of OnsetDD
113	E1bDateOfOnsetMM	Char	3	\$3.	E1b Date of OnsetMM
114	E1bDateOfOnsetYYYY	Num	8		E1b Date of OnsetYYYY
115	E1cPolydipsia	Char	7	\$7.	E1c Polydipsia

Num	Variable	Type	Len	Format	Label
116	E1cDateofOnsetDD	Num	8		E1c Date of OnsetDD
117	E1cDateofOnsetMM	Char	3	\$3.	E1c Date of OnsetMM
118	E1cDateofOnsetYYYY	Num	8		E1c Date of OnsetYYYY
119	E1dPolyphagia	Char	7	\$7.	E1d Polyphagia
120	E1dDateOfOnsetDD	Num	8		E1d Date of OnsetDD
121	E1dDateOfOnsetMM	Char	3	\$3.	E1d Date of OnsetMM
122	E1dDateOfOnsetYYYY	Num	8		E1d Date of OnsetYYYY
123	E1eUnexplainedWeightLoss	Char	7	\$7.	E1e Unexplained weight loss
124	f1availableWeightDD	Num	8		f1Most recent available weightsdd
125	f1availableWeightMM	Char	3	\$3.	f1Most recent available weightsMM
126	f1availableWeightYYYY	Num	8		f1Most recent available weightsYYYY
127	f1availableWeightWeight	Num	8		f1Most recent available weightsWeight
128	f1availableWeightUnits	Char	3	\$3.	f1Most recent available weightsUnits
129	f2availableWeightDD	Num	8		f2Most recent available weightsDD
130	f2availableWeightMM	Char	3	\$3.	f2Most recent available weightsMM
131	f2availableWeightYYYY	Num	8		f2Most recent available weightsYYYY
132	f2availableWeightWeight	Num	8		f2Most recent available weightsWeight
133	f2availableWeightUnits	Char	3	\$3.	f2Most recent available weightsUnits
134	f3availableWeightDD	Num	8		f3Most recent available weightsDD
135	f3availableWeightMM	Char	3	\$3.	f3Most recent available weightsMM
136	f3availableWeightYYYY	Num	8		f3Most recent available weightsYYYY
137	f3availableWeightWeight	Num	8		f3Most recent available weightsWeight
138	f3availableWeightUnits	Char	3	\$3.	f3Most recent available weightsUnits
139	F1DateStudyEndpointMetDD	Num	8		F1 Date Study Endpoint MetDD
140	F1DateStudyEndpointMetMM	Char	3	\$3.	F1 Date Study Endpoint MetMM
141	F1DateStudyEndpointMetYYYY	Num	8		F1 Date Study Endpoint MetYYYY
142	F2ClinicalDiagnosisDateDD	Num	8		F2Clinical Diagnosis Date DD
143	F2ClinicalDiagnosisDateMM	Char	3	\$3.	F2Clinical Diagnosis DateMM
144	F2ClinicalDiagnosisDateYYYY	Num	8		F2Clinical Diagnosis DateYYYY
145	H2OvernightHospitalization	Char	7	\$7.	H2Overnight Hospitalization
146	H3AdmissionToICU	Char	7	\$7.	H3AdmissionToICU
147	H5StartedInsulin	Char	7	\$7.	H5Started Insulin
148	NotificationStatus	Char	8	\$8.	Notification Status
149	H1OtherSymptoms	Char	7	\$7.	H1Other Symptoms
150	H4DKA	Char	7	\$7.	H4DKA
151	SiteInvestigatorAckStudyEndPoi	Char	3	\$3.	2aSite Investigator has acknowledged study results and confirms study end point met
152	DatestudyendpointmetDD	Num	8		1Date study endpoint metDD
153	DatestudyendpointmetMM	Char	3	\$3.	1Date study endpoint metMM
154	DatestudyendpointmetYYYY	Num	8		1Date study endpoint metYYYY

Num	Variable	Type	Len	Format	Label
155	D2aFastingPlasmaGlucUnits3_1	Char	6	\$6.	D2a Fasting GlucoseUnits
156	D2b2HourGlucUnits3_1	Char	6	\$6.	D2b 2 hour GlucoseUnits
157	D3RandomPlasmaGlucUnits2_1	Char	6	\$6.	D3 Random Plasma GlucoseUnits
158	D3RandomPlasmaGlucUnits3_1	Char	6	\$6.	D3 Random Plasma GlucoseUnits
159	D3RandomPlasmaGlucUnits4_1	Char	6	\$6.	D3 Random Plasma GlucoseUnits
160	D3RandomPlasmaGlucUnits5_1	Char	6	\$6.	D3 Random Plasma GlucoseUnits
161	D3RandomPlasmaGlucUnits6_1	Char	1	\$1.	D3 Random Plasma GlucoseUnits
162	D5MeterReadingLoc5_1	Char	9	\$9.	D5 Meter ReadingLocation
163	D5MeterReadingLoc6_1	Char	9	\$9.	D5 Meter ReadingLocation
164	D5MeterReadingLoc7_1	Char	9	\$9.	D5 Meter ReadingLocation
165	D5MeterReadingLoc8_1	Char	7	\$7.	D5 Meter ReadingLocation
166	D5MeterReadingLoc9_1	Char	7	\$7.	D5 Meter ReadingLocation
167	D5MeterReadingLoc10_1	Char	7	\$7.	D5 Meter ReadingLocation
168	D5MeterReadingLoc11_1	Char	7	\$7.	D5 Meter ReadingLocation
169	D5MeterReadingLoc12_1	Char	7	\$7.	D5 Meter ReadingLocation
170	D5MeterReadingLoc13_1	Char	7	\$7.	D5 Meter ReadingLocation
171	D5MeterReadingLoc14_1	Char	7	\$7.	D5 Meter ReadingLocation
172	D5MeterReadingLoc15_1	Char	7	\$7.	D5 Meter ReadingLocation
173	D5MeterReadingLoc16_1	Char	7	\$7.	D5 Meter ReadingLocation
174	D5MeterReadingUnit5_1	Char	6	\$6.	D5 Meter ReadingUnit
175	D5MeterReadingUnit6_1	Char	6	\$6.	D5 Meter ReadingUnit
176	D5MeterReadingUnit7_1	Char	6	\$6.	D5 Meter ReadingUnit
177	D5MeterReadingUnit8_1	Char	6	\$6.	D5 Meter ReadingUnit
178	D5MeterReadingUnit9_1	Char	6	\$6.	D5 Meter ReadingUnit
179	D5MeterReadingUnit10_1	Char	6	\$6.	D5 Meter ReadingUnit
180	D5MeterReadingUnit11_1	Char	6	\$6.	D5 Meter ReadingUnit
181	D5MeterReadingUnit12_1	Char	6	\$6.	D5 Meter ReadingUnit
182	D5MeterReadingUnit13_1	Char	6	\$6.	D5 Meter ReadingUnit
183	D5MeterReadingUnit14_1	Char	6	\$6.	D5 Meter ReadingUnit
184	D5MeterReadingUnit15_1	Char	6	\$6.	D5 Meter ReadingUnit
185	D5MeterReadingUnit16_1	Char	6	\$6.	D5 Meter ReadingUnit
186	D5OtherTestResultResult6_1	Char	4	\$4.	D6 Other Test ResultResult
187	D5OtherTestResultResult7_1	Char	4	\$4.	D6 Other Test ResultResult
188	D5OtherTestResultResult8_1	Char	3	\$3.	D6 Other Test ResultResult
189	D5OtherTestResultResult9_1	Char	5	\$5.	D6 Other Test ResultResult
190	D5OtherTestResultResult10_1	Char	4	\$4.	D6 Other Test ResultResult
191	D5OtherTestResultResult11_1	Char	4	\$4.	D6 Other Test ResultResult
192	D5OtherTestResultResult12_1	Char	3	\$3.	D6 Other Test ResultResult
193	D5OtherTestResultResult13_1	Char	5	\$5.	D6 Other Test ResultResult

Num	Variable	Type	Len	Format	Label
194	D5OtherTestResultResult14_1	Char	3	\$3.	D6 Other Test ResultResult
195	D5OtherTestResultResult15_1	Char	4	\$4.	D6 Other Test ResultResult
196	D5OtherTestResultResult16_1	Char	16	\$16.	D6 Other Test ResultResult
197	D5OtherTestResultResult17_1	Char	1	\$1.	D6 Other Test ResultResult
198	D5OtherTestResultResult18_1	Char	3	\$3.	D6 Other Test ResultResult
199	D5OtherTestResultResult19_1	Char	4	\$4.	D6 Other Test ResultResult
200	D5OtherTestResultResult20_1	Char	2	\$2.	D6 Other Test ResultResult
201	D5OtherTestResultResult21_1	Char	2	\$2.	D6 Other Test ResultResult
202	D5OtherTestResultResult22_1	Char	3	\$3.	D6 Other Test ResultResult
203	D5OtherTestResultResult23_1	Char	15	\$15.	D6 Other Test ResultResult
204	D6OtherTestResultUnit6_1	Char	7	\$7.	D6 Other Test ResultUnit
205	D6OtherTestResultUnit7_1	Char	8	\$8.	D6 Other Test ResultUnit
206	D6OtherTestResultUnit8_1	Char	6	\$6.	D6 Other Test ResultUnit
207	D6OtherTestResultUnit9_1	Char	6	\$6.	D6 Other Test ResultUnit
208	D6OtherTestResultUnit10_1	Char	5	\$5.	D6 Other Test ResultUnit
209	D6OtherTestResultUnit11_1	Char	4	\$4.	D6 Other Test ResultUnit
210	D6OtherTestResultUnit12_1	Char	6	\$6.	D6 Other Test ResultUnit
211	D6OtherTestResultUnit13_1	Char	6	\$6.	D6 Other Test ResultUnit
212	D6OtherTestResultUnit14_1	Char	7	\$7.	D6 Other Test ResultUnit
213	D6OtherTestResultUnit15_1	Char	1	\$1.	D6 Other Test ResultUnit
214	D6OtherTestResultUnit16_1	Char	1	\$1.	D6 Other Test ResultUnit
215	D6OtherTestResultUnit17_1	Char	1	\$1.	D6 Other Test ResultUnit
216	D6OtherTestResultUnit18_1	Char	6	\$6.	D6 Other Test ResultUnit
217	D6OtherTestResultUnit19_1	Char	1	\$1.	D6 Other Test ResultUnit
218	D6OtherTestResultUnit20_1	Char	4	\$4.	D6 Other Test ResultUnit
219	D6OtherTestResultUnit21_1	Char	6	\$6.	D6 Other Test ResultUnit
220	D6OtherTestResultUnit22_1	Char	6	\$6.	D6 Other Test ResultUnit
221	D6OtherTestResultUnit23_1	Char	1	\$1.	D6 Other Test ResultUnit
222	testName6_1	Char	22	\$22.	Test Name
223	testName7_1	Char	17	\$17.	Test Name
224	testName8_1	Char	7	\$7.	Test Name
225	testName9_1	Char	20	\$20.	Test Name
226	testName10_1	Char	15	\$15.	Test Name
227	testName11_1	Char	4	\$4.	Test Name
228	testName12_1	Char	4	\$4.	Test Name
229	testName13_1	Char	11	\$11.	Test Name
230	testName14_1	Char	9	\$9.	Test Name
231	testName15_1	Char	3	\$3.	Test Name
232	testName16_1	Char	13	\$13.	Test Name

Num	Variable	Type	Len	Format	Label
233	testName17_1	Char	19	\$19.	Test Name
234	testName18_1	Char	11	\$11.	Test Name
235	testName19_1	Char	15	\$15.	Test Name
236	testName20_1	Char	4	\$4.	Test Name
237	testName21_1	Char	4	\$4.	Test Name
238	testName22_1	Char	11	\$11.	Test Name
239	testName23_1	Char	13	\$13.	Test Name
240	D2aFastingPlasmaGlucMM3_1	Char	3	\$3.	D2a Fasting GlucoseMM
241	D2b2HourGlucMM3_1	Char	3	\$3.	D2b 2 hour GlucoseMM
242	D3RandomPlasmaGlucMM2_1	Char	3	\$3.	D3 Random Plasma GlucoseMM
243	D3RandomPlasmaGlucMM3_1	Char	3	\$3.	D3 Random Plasma GlucoseMM
244	D3RandomPlasmaGlucMM4_1	Char	3	\$3.	D3 Random Plasma GlucoseMM
245	D3RandomPlasmaGlucMM5_1	Char	3	\$3.	D3 Random Plasma GlucoseMM
246	D3RandomPlasmaGlucMM6_1	Char	1	\$1.	D3 Random Plasma GlucoseMM
247	D4HbA1cMM3_1	Char	3	\$3.	D4 HbA1cMM
248	D4HbA1cMM4_1	Char	3	\$3.	D4 HbA1cMM
249	D5MeterReadingMM5_1	Char	3	\$3.	D5 Meter ReadingMM
250	D5MeterReadingMM6_1	Char	3	\$3.	D5 Meter ReadingMM
251	D5MeterReadingMM7_1	Char	3	\$3.	D5 Meter ReadingMM
252	D5MeterReadingMM8_1	Char	3	\$3.	D5 Meter ReadingMM
253	D5MeterReadingMM9_1	Char	3	\$3.	D5 Meter ReadingMM
254	D5MeterReadingMM10_1	Char	3	\$3.	D5 Meter ReadingMM
255	D5MeterReadingMM11_1	Char	3	\$3.	D5 Meter ReadingMM
256	D5MeterReadingMM12_1	Char	3	\$3.	D5 Meter ReadingMM
257	D5MeterReadingMM13_1	Char	3	\$3.	D5 Meter ReadingMM
258	D5MeterReadingMM14_1	Char	3	\$3.	D5 Meter ReadingMM
259	D5MeterReadingMM15_1	Char	3	\$3.	D5 Meter ReadingMM
260	D5MeterReadingMM16_1	Char	3	\$3.	D5 Meter ReadingMM
261	D5OtherTestResultMM6_1	Char	3	\$3.	D6 Other Test ResultMM
262	D5OtherTestResultMM7_1	Char	3	\$3.	D6 Other Test ResultMM
263	D5OtherTestResultMM8_1	Char	3	\$3.	D6 Other Test ResultMM
264	D5OtherTestResultMM9_1	Char	3	\$3.	D6 Other Test ResultMM
265	D5OtherTestResultMM10_1	Char	3	\$3.	D6 Other Test ResultMM
266	D5OtherTestResultMM11_1	Char	3	\$3.	D6 Other Test ResultMM
267	D5OtherTestResultMM12_1	Char	3	\$3.	D6 Other Test ResultMM
268	D5OtherTestResultMM13_1	Char	3	\$3.	D6 Other Test ResultMM
269	D5OtherTestResultMM14_1	Char	3	\$3.	D6 Other Test ResultMM
270	D5OtherTestResultMM15_1	Char	3	\$3.	D6 Other Test ResultMM
271	D5OtherTestResultMM16_1	Char	3	\$3.	D6 Other Test ResultMM

Num	Variable	Type	Len	Format	Label
272	D5OtherTestResultMM17_1	Char	3	\$.	D6 Other Test ResultMM
273	D5OtherTestResultMM18_1	Char	3	\$.	D6 Other Test ResultMM
274	D5OtherTestResultMM19_1	Char	3	\$.	D6 Other Test ResultMM
275	D5OtherTestResultMM20_1	Char	3	\$.	D6 Other Test ResultMM
276	D5OtherTestResultMM21_1	Char	3	\$.	D6 Other Test ResultMM
277	D5OtherTestResultMM22_1	Char	3	\$.	D6 Other Test ResultMM
278	D5OtherTestResultMM23_1	Char	3	\$.	D6 Other Test ResultMM
279	D2aFastingPlasmaGlucDD3_1	Num	8		D2a Fasting GlucoseDD
280	D2aFastingPlasmaGlucResult3_1	Num	8		D2a Fasting GlucoseResult
281	D2aFastingPlasmaGlucYYYY3_1	Num	8		D2a Fasting GlucoseYYYY
282	D2b2HourGlucDD3_1	Num	8		D2b 2 hour GlucoseDD
283	D2b2HourGlucResult3_1	Num	8		D2b 2 hour GlucoseResult
284	D2b2HourGlucYYYY3_1	Num	8		D2b 2 hour GlucoseYYYY
285	D3RandomPlasmaGlucDD2_1	Num	8		D3 Random Plasma GlucoseDD
286	D3RandomPlasmaGlucDD3_1	Num	8		D3 Random Plasma GlucoseDD
287	D3RandomPlasmaGlucDD4_1	Num	8		D3 Random Plasma GlucoseDD
288	D3RandomPlasmaGlucDD5_1	Num	8		D3 Random Plasma GlucoseDD
289	D3RandomPlasmaGlucDD6_1	Num	8		D3 Random Plasma GlucoseDD
290	D3RandomPlasmaGlucResult2_1	Num	8		D3 Random Plasma GlucoseResult
291	D3RandomPlasmaGlucResult3_1	Num	8		D3 Random Plasma GlucoseResult
292	D3RandomPlasmaGlucResult4_1	Num	8		D3 Random Plasma GlucoseResult
293	D3RandomPlasmaGlucResult5_1	Num	8		D3 Random Plasma GlucoseResult
294	D3RandomPlasmaGlucResult6_1	Num	8		D3 Random Plasma GlucoseResult
295	D3RandomPlasmaGlucYYYY2_1	Num	8		D3 Random Plasma GlucoseYYYY
296	D3RandomPlasmaGlucYYYY3_1	Num	8		D3 Random Plasma GlucoseYYYY
297	D3RandomPlasmaGlucYYYY4_1	Num	8		D3 Random Plasma GlucoseYYYY
298	D3RandomPlasmaGlucYYYY5_1	Num	8		D3 Random Plasma GlucoseYYYY
299	D3RandomPlasmaGlucYYYY6_1	Num	8		D3 Random Plasma GlucoseYYYY
300	D4HbA1cDD3_1	Num	8		D4 HbA1cDD
301	D4HbA1cDD4_1	Num	8		D4 HbA1cDD
302	D4HbA1cResult3_1	Num	8		D4 HbA1cResult
303	D4HbA1cResult4_1	Num	8		D4 HbA1cResult
304	D4HbA1cYYYY3_1	Num	8		D4 HbA1cYYYY
305	D4HbA1cYYYY4_1	Num	8		D4 HbA1cYYYY
306	D5MeterReadingDD5_1	Num	8		D5 Meter ReadingDD
307	D5MeterReadingDD6_1	Num	8		D5 Meter ReadingDD
308	D5MeterReadingDD7_1	Num	8		D5 Meter ReadingDD
309	D5MeterReadingDD8_1	Num	8		D5 Meter ReadingDD
310	D5MeterReadingDD9_1	Num	8		D5 Meter ReadingDD

Num	Variable	Type	Len	Format	Label
311	D5MeterReadingDD10_1	Num	8		D5 Meter ReadingDD
312	D5MeterReadingDD11_1	Num	8		D5 Meter ReadingDD
313	D5MeterReadingDD12_1	Num	8		D5 Meter ReadingDD
314	D5MeterReadingDD13_1	Num	8		D5 Meter ReadingDD
315	D5MeterReadingDD14_1	Num	8		D5 Meter ReadingDD
316	D5MeterReadingDD15_1	Num	8		D5 Meter ReadingDD
317	D5MeterReadingDD16_1	Num	8		D5 Meter ReadingDD
318	D5MeterReadingResult5_1	Num	8		D5 Meter ReadingResult
319	D5MeterReadingResult6_1	Num	8		D5 Meter ReadingResult
320	D5MeterReadingResult7_1	Num	8		D5 Meter ReadingResult
321	D5MeterReadingResult8_1	Num	8		D5 Meter ReadingResult
322	D5MeterReadingResult9_1	Num	8		D5 Meter ReadingResult
323	D5MeterReadingResult10_1	Num	8		D5 Meter ReadingResult
324	D5MeterReadingResult11_1	Num	8		D5 Meter ReadingResult
325	D5MeterReadingResult12_1	Num	8		D5 Meter ReadingResult
326	D5MeterReadingResult13_1	Num	8		D5 Meter ReadingResult
327	D5MeterReadingResult14_1	Num	8		D5 Meter ReadingResult
328	D5MeterReadingResult15_1	Num	8		D5 Meter ReadingResult
329	D5MeterReadingResult16_1	Num	8		D5 Meter ReadingResult
330	D5MeterReadingYYYY5_1	Num	8		D5 Meter ReadingYYYY
331	D5MeterReadingYYYY6_1	Num	8		D5 Meter ReadingYYYY
332	D5MeterReadingYYYY7_1	Num	8		D5 Meter ReadingYYYY
333	D5MeterReadingYYYY8_1	Num	8		D5 Meter ReadingYYYY
334	D5MeterReadingYYYY9_1	Num	8		D5 Meter ReadingYYYY
335	D5MeterReadingYYYY10_1	Num	8		D5 Meter ReadingYYYY
336	D5MeterReadingYYYY11_1	Num	8		D5 Meter ReadingYYYY
337	D5MeterReadingYYYY12_1	Num	8		D5 Meter ReadingYYYY
338	D5MeterReadingYYYY13_1	Num	8		D5 Meter ReadingYYYY
339	D5MeterReadingYYYY14_1	Num	8		D5 Meter ReadingYYYY
340	D5MeterReadingYYYY15_1	Num	8		D5 Meter ReadingYYYY
341	D5MeterReadingYYYY16_1	Num	8		D5 Meter ReadingYYYY
342	D5OtherTestResultDD6_1	Num	8		D6 Other Test ResultDD
343	D5OtherTestResultDD7_1	Num	8		D6 Other Test ResultDD
344	D5OtherTestResultDD8_1	Num	8		D6 Other Test ResultDD
345	D5OtherTestResultDD9_1	Num	8		D6 Other Test ResultDD
346	D5OtherTestResultDD10_1	Num	8		D6 Other Test ResultDD
347	D5OtherTestResultDD11_1	Num	8		D6 Other Test ResultDD
348	D5OtherTestResultDD12_1	Num	8		D6 Other Test ResultDD
349	D5OtherTestResultDD13_1	Num	8		D6 Other Test ResultDD

Num	Variable	Type	Len	Format	Label
350	D5OtherTestResultDD14_1	Num	8		D6 Other Test ResultDD
351	D5OtherTestResultDD15_1	Num	8		D6 Other Test ResultDD
352	D5OtherTestResultDD16_1	Num	8		D6 Other Test ResultDD
353	D5OtherTestResultDD17_1	Num	8		D6 Other Test ResultDD
354	D5OtherTestResultDD18_1	Num	8		D6 Other Test ResultDD
355	D5OtherTestResultDD19_1	Num	8		D6 Other Test ResultDD
356	D5OtherTestResultDD20_1	Num	8		D6 Other Test ResultDD
357	D5OtherTestResultDD21_1	Num	8		D6 Other Test ResultDD
358	D5OtherTestResultDD22_1	Num	8		D6 Other Test ResultDD
359	D5OtherTestResultDD23_1	Num	8		D6 Other Test ResultDD
360	D5OtherTestResultYYYY6_1	Num	8		D6 Other Test ResultYYYY
361	D5OtherTestResultYYYY7_1	Num	8		D6 Other Test ResultYYYY
362	D5OtherTestResultYYYY8_1	Num	8		D6 Other Test ResultYYYY
363	D5OtherTestResultYYYY9_1	Num	8		D6 Other Test ResultYYYY
364	D5OtherTestResultYYYY10_1	Num	8		D6 Other Test ResultYYYY
365	D5OtherTestResultYYYY11_1	Num	8		D6 Other Test ResultYYYY
366	D5OtherTestResultYYYY12_1	Num	8		D6 Other Test ResultYYYY
367	D5OtherTestResultYYYY13_1	Num	8		D6 Other Test ResultYYYY
368	D5OtherTestResultYYYY14_1	Num	8		D6 Other Test ResultYYYY
369	D5OtherTestResultYYYY15_1	Num	8		D6 Other Test ResultYYYY
370	D5OtherTestResultYYYY16_1	Num	8		D6 Other Test ResultYYYY
371	D5OtherTestResultYYYY17_1	Num	8		D6 Other Test ResultYYYY
372	D5OtherTestResultYYYY18_1	Num	8		D6 Other Test ResultYYYY
373	D5OtherTestResultYYYY19_1	Num	8		D6 Other Test ResultYYYY
374	D5OtherTestResultYYYY20_1	Num	8		D6 Other Test ResultYYYY
375	D5OtherTestResultYYYY21_1	Num	8		D6 Other Test ResultYYYY
376	D5OtherTestResultYYYY22_1	Num	8		D6 Other Test ResultYYYY
377	D5OtherTestResultYYYY23_1	Num	8		D6 Other Test ResultYYYY

Data Set Name: tn01_nh09_followupmissedvisit.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Visit Date
3	Visit	Char	48		Visit
4	ParticipantContacted	Char	3		Was the participant contacted
5	ParticipantExpectedToContinue	Char	3		Is the participant expected to continue with future followup visits
6	ParticipantWillingToContinueMe	Char	1		Participant willing to continue
7	ReasonParticipantMissed	Char	710		Reason participant missed
8	MotherBabyWillingToContinueTak	Char	3		Mother baby willing to continue tak
9	ParticipantAgreeToContinue	Char	3		Participant agree to continue
10	ReasonForMissedVisit	Char	83		Reason for missed visit
11	ReasonForMissedVisitSpecify	Char	665		Reason for missed visit specify
12	MissedVisitInfant	Char	1		Missed visit infant
13	VistMissed	Char	18		Visit missed

Data Set Name: tn01_nh10_dtp1entry.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	ParticipantDiagnosedWithT1D	Char	3	\$3.	Has the participant been diagnosed with type 1 diabetes T1D
5	ParticipantPregnant	Char	14	\$14.	For females of child bearing agepotential is the participant currently pregnant
6	ParticipantUsedInsulinOrOtherG	Char	2	\$2.	Has the participant ever previously used or is currently using medications for the control of hyperglycemia eg insulin oral hypoglycemic agents including sulfonylureas metformin thiazolidinediones alphaglucoasidase inhibitors meglitinides GLP1 mimetics and
7	DateConsentSignedDay	Num	8		Date signed informed consent form day
8	DateConsentSignedMonth	Char	3	\$3.	Date signed Informed Consent form month
9	DateConsentSignedYear	Num	8		Date signed Informed Consent form year
10	PermissionForSampleStorage	Char	3	\$3.	Storage of hisher samples for future testing
11	BirthMonth	Char	3	\$3.	Participant Birth Month
12	BirthYear	Num	8		Participant Birth Year
13	Sex	Char	6	\$6.	Participant Sex
14	Ethnicity	Char	22	\$22.	Participant Ethnicity
15	Race_AmericanIndianorAlaskaNat	Num	8		Race: American Indian or Alaska Native
16	Race_Asian	Num	8		Race: Asian
17	Race_BlackorAfricanAmerican	Num	8		Race: Black or African American
18	Race_NativeHawaiianorOtherPaci	Num	8		Race: Native Hawaiian or Other Pacific Islander
19	Race_White	Num	8		Race: White
20	Race_Unknownornotreported	Num	8		Race: Unknown or not reported
21	Race_Refused	Num	8		Race: Refused
22	OtherSpecify	Char	7	\$7.	Participant Race other specify
23	DPT1ParticipantIDNumber	Char	9	\$9.	Did the participant participate in DPT1 if Yes record the DPT1 participant ID number
24	NumOfRelativesWithT1D	Num	8		How many of the participants blood relatives have type 1 diabetes including deceased relatives
25	RelativeWithT1D1_1	Char	17	\$17.	Relative with Type 1 Diabetes
26	SexOfRelativeWithT1D1_1	Char	6	\$6.	Sex of Relative
27	AgeOfRelativeWithT1D1_1	Num	8		Current Age of Relative
28	AgeOfOnsetInRelativeWithT1D1_1	Num	8		Age of Onset in Relative
29	AgeRelativeWithT1DStartedIn1_1	Num	8		Age Relative Started Insulin
30	RelativeComments1_1	Char	22	\$22.	Relative Comments
31	RelativeWithT1D2_1	Char	21	\$21.	Relative with Type 1 Diabetes
32	SexOfRelativeWithT1D2_1	Char	6	\$6.	Sex of Relative
33	AgeOfRelativeWithT1D2_1	Num	8		Current Age of Relative
34	AgeOfOnsetInRelativeWithT1D2_1	Num	8		Age of Onset in Relative
35	AgeRelativeWithT1DStartedIn2_1	Num	8		Age Relative Started Insulin

Num	Variable	Type	Len	Format	Label
36	RelativeComments2_1	Char	26	\$26.	Relative Comments
37	RelativeWithT1D3_1	Char	17	\$17.	Relative with Type 1 Diabetes
38	SexOfRelativeWithT1D3_1	Char	6	\$6.	Sex of Relative
39	AgeOfRelativeWithT1D3_1	Num	8		Current Age of Relative
40	AgeOfOnsetInRelativeWithT1D3_1	Num	8		Age of Onset in Relative
41	AgeRelativeWithT1DStartedIn3_1	Num	8		Age Relative Started Insulin
42	RelativeComments3_1	Char	12	\$12.	Relative Comments
43	RelativeWithT1D4_1	Char	17	\$17.	Relative with Type 1 Diabetes
44	SexOfRelativeWithT1D4_1	Char	6	\$6.	Sex of Relative
45	AgeOfRelativeWithT1D4_1	Num	8		Current Age of Relative
46	AgeOfOnsetInRelativeWithT1D4_1	Num	8		Age of Onset in Relative
47	AgeRelativeWithT1DStartedIn4_1	Num	8		Age Relative Started Insulin
48	RelativeComments4_1	Char	38	\$38.	Relative Comments
49	RelativeWithT1D5_1	Char	13	\$13.	Relative with Type 1 Diabetes
50	SexOfRelativeWithT1D5_1	Char	4	\$4.	Sex of Relative
51	AgeOfRelativeWithT1D5_1	Num	8		Current Age of Relative
52	AgeOfOnsetInRelativeWithT1D5_1	Num	8		Age of Onset in Relative
53	AgeRelativeWithT1DStartedIn5_1	Num	8		Age Relative Started Insulin
54	RelativeComments5_1	Char	8	\$8.	Relative Comments
55	RelativeWithT1D6_1	Char	1	\$1.	Relative with Type 1 Diabetes
56	SexOfRelativeWithT1D6_1	Char	1	\$1.	Sex of Relative
57	AgeOfRelativeWithT1D6_1	Num	8		Current Age of Relative
58	AgeOfOnsetInRelativeWithT1D6_1	Num	8		Age of type 1 diabetes onset in relative
59	AgeRelativeWithT1DStartedIn6_1	Num	8		Age relative started insulin
60	RelativeComments6_1	Char	1	\$1.	Relative comments
61	RelativeWithT1D7_1	Char	1	\$1.	Relative with type 1 diabetes
62	SexOfRelativeWithT1D7_1	Char	1	\$1.	Sex of relative
63	AgeOfRelativeWithT1D7_1	Num	8		Current age of relative
64	AgeOfOnsetInRelativeWithT1D7_1	Num	8		Age of onset in relative
65	AgeRelativeWithT1DStartedIn7_1	Num	8		Age relative started insulin
66	RelativeComments7_1	Char	1	\$1.	Relative comments
67	RelativeWithT1D8_1	Char	1	\$1.	Relative with type 1 diabetes
68	SexOfRelativeWithT1D8_1	Char	1	\$1.	Sex of relative
69	AgeOfRelativeWithT1D8_1	Num	8		Current age of relative
70	AgeOfOnsetInRelativeWithT1D8_1	Num	8		Age of onset in relative
71	AgeRelativeWithT1DStartedIn8_1	Num	8		Age relative started insulin
72	RelativeComments8_1	Char	1	\$1.	Relative comments
73	InflammatoryBowelDiseaseWithin	Char	2		Inflammatory Bowel Disease Within 6 Months
74	AsthmaEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has asthma ever

Num	Variable	Type	Len	Format	Label
75	CeliacDiseaseEver	Char	2	\$2.	Has the participant been told by a physician that they he/she has celiac disease ever
76	AddisonsDiseaseEver	Char	2	\$2.	Has the participant been told by a physician that they he/she has addisons disease ever
77	VitiligoEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has vitiligo ever
78	ThyroidDiseaseEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has thyroid disease ever
79	PsoriasisEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has psoriasis ever
80	AlopeciaEver	Char	2	\$2.	Has the participant been told by a physician that they he/she has alopecia ever
81	RheumatologicEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has rheumatologic disease ever
82	AllergiesEver	Char	3	\$3.	Has the participant been told by a physician that they he/she has allergies ever
83	CancerEver	Char	2	\$2.	Has the participant ever be
84	ColitisOrColonProblemsEver	Char	3	\$3.	Colitis or colon problems ever
85	ColitisOrColonProblemsWithinLa	Char	3	\$3.	Has the participant been told by a physician that they he/she has colitis or colon problems
86	CongenitalHeartDiseaseEver	Char	3	\$3.	Congenital heart disease or heart problems ever
87	CongenitalHeartDiseaseWithinLa	Char	2	\$2.	Has the participant been told by a physician that they he/she has congenital heart disease
88	EpilepsyConvulsionsSeizuresEve	Char	3	\$3.	Epilepsy convulsions or seizures ever
89	EpilepsyConvulsionsSeizuresWit	Char	3	\$3.	Has the participant been told by a physician that they he/she has epilepsy convulsions or seizures
90	HepatitisOrLiverDiseaseEver	Char	2	\$2.	Hepatitis Liver disease ever
91	HepatitisOrLiverDiseaseWithinL	Char	2	\$2.	Has the participant been told by a physician that they he/she has hepatitis or liver disease
92	HighBPever	Char	3	\$3.	High blood pressure ever
93	HighCholesterolEver	Char	3		High Cholesterol ever
94	InfectiousMononucleosisEver	Char	3	\$3.	Infectious mononucleosis ever
95	InfectiousMononucleosisWithinL	Char	3	\$3.	Has the participant been told by a physician that they he/she has infectious mononucleosis
96	LimitedLifeExpectancyOrImmunno	Char	3	\$3.	Has the participant been told by a physician that he/she has diseases likely to limit life expectancy or lead to use of immunosuppressive or immunomodulatory therapies ever
97	LimitedLifeExpectancyOrImmunos	Char	3	\$3.	Limited Life Expectancy or immunosuppressive or immunomodulatory therapies
98	PerniciousAnemiaEver	Char	2	\$2.	Pernicious anemia ever
99	UlcerEver	Char	3	\$3.	Ulcer stomach or duodenal ever
100	OtherAutoimmuneDiseasesWithinL	Char	3	\$3.	Has the participant been told by a physician that they he/she has other autoimmune diseases
101	OtherAutoimmuneDiseasesSpecify	Char	37	\$37.	Has the participant been told by a physician that they he/she has other autoimmune diseases specify
102	AsthmaWithinLast6Months	Char	3		Asthma Within Last 6 Months
103	CeliacDiseaseWithinLast6Months	Char	2		Celiac Disease Within Last 6 Months
104	AddisonsDiseaseWithinLast6Months	Char	2		Addisons Disease Within Last 6 Months
105	VitiligoWithinLast6Months	Char	2		Vitiligo Within Last 6 Months
106	ThyroidDiseaseWithinLast6Months	Char	3		Thyroid Disease Within Last 6 Months
107	PsoriasisWithinLast6Months	Char	3		Psoriasis Within Last 6 Months
108	AlopeciaWithinLast6Months	Char	3		Alopecia Within Last 6 Months

Num	Variable	Type	Len	Format	Label
109	RheumatologicWithinLast6Months	Char	3		Rheumatologic Within Last 6 Months
110	MultipleSclerosisWithinLast6Mo	Char	2		Multiple Sclerosis Within Last 6 Months
111	AllergiesWithinLast6Months	Char	3		Allergies Within Last 6 Months
112	CancerWithinLast6Months	Char	2		Cancer Within Last 6 Months
113	HighBPwithinLast6Months	Char	3		High BP Within Last 6 Months
114	HighCholesterolWithinLast6Months	Char	3		High Cholesterol Within Last 6 Months
115	PerniciousAnemiaWithinLast6Mo	Char	2		PerniciousAnemia Within Last 6 Months
116	UlcerWithinLast6Months	Char	2		Ulcer Within Last 6 Months
117	YESSpecify	Char	72	\$72.	YES Specify
118	Corticosteroids	Char	3	\$3.	Is the participant taking corticosteroids
119	SteroidsSpecify	Char	11	\$11.	Is the participant taking steroids specify
120	ImmunosuppressiveTherapies	Char	2	\$2.	Is the participant taking immunosuppressive therapies
121	ImmunosuppressiveTherapiesSpec	Char	1	\$1.	Is the participant taking immunosuppressive therapies specify
122	SeatedArmBPSystolic	Num	8		Seated arm blood pressure systolic
123	SeatedArmBPDiastolic	Num	8		Seated arm blood pressure diastolic
124	Weightkg	Num	8		Weight in kilograms
125	Weightlbs	Num	8		Weight in pounds
126	Heightcm	Num	8		Height in centimeters
127	Heightin	Num	8		Height in inches
128	SeatedHeartRate	Num	8		Seated heart rate
129	SeatedRespiratoryRate	Num	8		Seated respiratory rate
130	AlphaGlucosidaseInhibitors	Char	2	\$2.	Is the participant taking alpha glucosidase inhibitors
131	AntibodySampleCollected	Char	3	\$3.	Antibody sample collected
132	Antibodycomment	Char	32	\$32.	Antibody comment
133	BetaBlockers	Char	3	\$3.	Is the participant taking beta blockers
134	BetaBlockersSpecify	Char	14	\$14.	Is the participant taking beta blockers specify
135	BlodForDNASampleCollected	Char	3	\$3.	Blood for DNA sample collected
136	BlodForDNAComment	Char	1	\$1.	Blood for DNA comment
137	BloodForCellsSampleCollected	Char	3	\$3.	Blood for cells sample collected
138	BloodForCellsComment	Char	76	\$76.	Blood for cells comment
139	BloodForRNASampleCollected	Char	3	\$3.	Blood for RNA sample collected
140	BloodForRNAComment	Char	76	\$76.	Blood for RNA comment
141	ConsenToContinuedStorageOfBloo	Char	3	\$3.	Did the participant consent to continued storage of
142	Diphenylhydantoin	Char	3	\$3.	Is the participant taking diphenylhydantoin
143	DiphenylhydantoinSpecify	Char	1	\$1.	Is participant currently taking diphenylhydantoin if yes specify
144	HbA1cSamplesCollected	Char	3	\$3.	HbA1c sample collected
145	HbA1cComment	Char	1	\$1.	HbA1c comment
146	Meglitinides	Char	2		Is the participant taking Meglitinides
147	Metformin	Char	2	\$2.	Is the participant taking metformin

Num	Variable	Type	Len	Format	Label
148	Niacin	Char	3	\$3.	Is the participant taking niacin
149	OGTTSampleCollected	Char	3	\$3.	OGTT Sample Collected
150	OGTTComment	Char	48	\$48.	OGTT Comment
151	OtherGlucoseLoweringAgents	Char	2	\$2.	Is the participant taking other glucose lowering agents
152	PlasmaSampleCollected	Char	3	\$3.	Plasma Sample Collected
153	PlasmaComment	Char	76	\$76.	Plasma Sample comment
154	PotassiumDepletingDiurectics	Char	2	\$2.	Is the participant taking potassium depleting diuretics
155	PotassiumDepletingDiurecticsSp	Char	1	\$1.	Is the participant taking potassium depleting diuretics specify
156	SerumForProteomicsSampleCollec	Char	3	\$3.	Sample collected for serum proteomics
157	SerumForProteomicsComment	Char	35	\$35.	Serum for proteomics comment
158	SerumMechanisticSerumSampleCol	Char	3	\$3.	Sample collected for serum mechanistic
159	SerumMechanisticSerumComment	Char	1	\$1.	Serum mechanistic comment
160	Thiazolidinediones	Char	2	\$2.	Is the participant taking thiazolidinediones
161	WholeBloodPBMCPlasmaSampleColl	Char	3	\$3.	Sample collected for whole blood PBMC plasma
162	WholeBloodPBMCPlasmaComment	Char	1	\$1.	Whole Blood PBMC Plasma Comment
163	DateSignedNEWInformedConsentFo	Num	8		Date participant signed the informed consent form
164	DateSignedNEWInformedConsentFo2	Char	3	\$3.	Date participant signed the informed consent form
165	DateSignedNEWInformedConsentFo3	Num	8		Date participant signed the informed consent form
166	MechanisticSampleCollectionDay	Num	8		Mechanistic Sample Collection Day
167	MechanisticSampleCollectionMon	Char	3	\$3.	Mechanistic Sample Collection Mon
168	MechanisticSampleCollectionYea	Num	8		Mechanistic Sample Collection Yea
169	SamplesCollectionDay	Num	8		SamplesCollection Day
170	SamplesCollectionMonth	Char	3	\$3.	Samples Collection Month
171	SamplesCollectionYear	Num	8		Samples Collection Year

Data Set Name: tn01_nh12_controlentry.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	ParticipantDiagnosedWithT1D	Char	2	\$2.	Has the participant been diagnosed with type 1 diabetes T1D
5	ParticipantUsedInsulinOrOtherG	Char	2	\$2.	Has the participant ever previously used or is currently using medications for the control of hyperglycemia (e.g. Insulin, Oral Hypoglycemic agents including Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Meglitinides, GLP-1 Mi
6	ParticipantHasKnownSevereActiv	Char	2	\$2.	Does the participant have known severe inactive diseases and/or diseases which are likely to limit life expectancy or lead to use of immunosuppressive or immunomodulatory therapies during the course of the study
7	ParticipantPregnant	Char	14	\$14.	For females of child bearing age/potential is the participant currently pregnant
8	ConsenToContinuedStorageOfBloo	Char	14	\$14.	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
9	DateSignedInformedConsentFormD	Num	8		Monitoring informed consent form signed day
10	DateSignedInformedConsentFormM	Char	3	\$3.	Monitoring informed consent form signed month
11	DateSignedInformedConsentFormY	Num	8		Monitoring informed consent form signed year
12	AsthmaEver	Char	3	\$3.	Asthma ever
13	AsthmaWithinLastYear	Char	3	\$3.	Asthma within last year
14	CeliacDiseaseEver	Char	3	\$3.	Celiac disease ever
15	CeliacDiseaseWithinLastYear	Char	3	\$3.	Celiac disease within the last year
16	InflammatoryBowelDiseaseEver	Char	2		Inflammatory bowel disease ever
17	InflammatoryBowelDiseaseWithin	Char	2		Inflammatory bowel disease within last year
18	AddisonsDiseaseEver	Char	2	\$2.	Addisons disease ever
19	AddisonsDiseaseWithinLastYear	Char	2	\$2.	Addisons disease within the last year
20	VitiligoEver	Char	2	\$2.	Vitiligo ever
21	VitiligoWithinLastYear	Char	2	\$2.	Vitiligo within the last year
22	ThyroidDiseaseEver	Char	3	\$3.	Thyroid disease ever
23	ThyroidDiseaseWithinLastYear	Char	3	\$3.	Thyroid disease within the last year
24	PsoriasisEver	Char	3	\$3.	Psoriasis ever
25	PsoriasisWithinLastYear	Char	2	\$2.	Psoriasis within the last year
26	AlopeciaEver	Char	3	\$3.	Alopecia hair loss ever
27	AlopeciaWithinLastYear	Char	3	\$3.	Alopecia hair loss within the last year
28	RheumatologicEver	Char	3	\$3.	Rheumatologic disease ever
29	RheumatologicWithinLastYear	Char	3	\$3.	Rheumatologic disease within the last year
30	MultipleSclerosisEver	Char	2	\$2.	Multiple sclerosis ever
31	MultipleSclerosisWithinLastYea	Char	2	\$2.	Multiple sclerosis within last year
32	OtherAutoimmuneDiseasesEver	Char	2	\$2.	Other autoimmune diseases ever
33	OtherAutoimmuneDiseasesWithinL	Char	2	\$2.	Other autoimmune diseases within last year
34	OtherAutoimmuneDiseasesSpecify	Char	1	\$1.	Other autoimmune diseases specify

Num	Variable	Type	Len	Format	Label
35	AllergiesEver	Char	3	\$3.	Allergies ever
36	AllergiesWithinLastYear	Char	3	\$3.	Allergies within last year
37	CancerEver	Char	2	\$2.	Cancer ever
38	CancerWithinLastYear	Char	2	\$2.	Cancer within the last year
39	ColitisOrColonProblemsEver	Char	3	\$3.	Colitis or colon problems ever
40	ColitisOrColonProblemsWithinLa	Char	3	\$3.	Colitis or colon problems within the last year
41	CongenitalHeartDiseaseEver	Char	3	\$3.	Congenital heart disease or heart problems ever
42	CongenitalHeartDiseaseWithinLa	Char	2	\$2.	Congenital heart disease or heart problems within the last year
43	EpilepsyConvulsionsSeizuresEve	Char	2	\$2.	Epilepsy convulsions or seizures ever
44	EpilepsyConvulsionsSeizuresWit	Char	2	\$2.	Epilepsy convulsions or seizures within the last year
45	HepatitisOrLiverDiseaseEver	Char	2	\$2.	Hepatitis or liver disease ever
46	HepatitisOrLiverDiseaseWithinL	Char	2	\$2.	Hepatitis or liver disease within the last year
47	HighBPever	Char	2	\$2.	High blood pressure ever
48	HighBPwithinLastYear	Char	2	\$2.	High blood pressure within last year
49	HighCholesterolEver	Char	3		High cholesterol ever
50	HighCholesterolWithinLastYear	Char	3		High cholesterol within last year
51	InfectiousMononucleosisEver	Char	3	\$3.	Infectious mononucleosis ever
52	InfectiousMononucleosisWithinL	Char	2	\$2.	Infectious mononucleosis within the last year
53	PerniciousAnemiaEver	Char	2	\$2.	Pernicious anemia ever
54	PerniciousAnemiaWithinLastYear	Char	2	\$2.	Pernicious anemia within the last year
55	UlcerEver	Char	3	\$3.	Ulcer stomach or duodenal ever
56	UlcerWithinLastYear	Char	2	\$2.	Ulcer stomach or duodenal within the last year
57	SeatedArmBPSystolic	Num	8		Systolic seated arm blood pressure
58	SeatedArmBPDiastolic	Num	8		Diastolic seated arm blood pressure
59	Weightkg	Num	8		Weight in kgs
60	Weightlbs	Num	8		Weight in lbs
61	Weight	Char	8	\$8.	Weight
62	Heightcm	Num	8		Height in cm
63	Heightin	Num	8		Height in inches
64	Height	Char	8	\$8.	Height
65	SeatedHeartRate	Num	8		Seated heart rate
66	SeatedRespiratoryRate	Num	8		Seated respiratory rate
67	AlphaGlucosidaselInhibitors	Char	1	\$1.	Alpha glucosidase inhibitors
68	BetaBlockers	Char	2	\$2.	Currently taking beta blockers
69	BetaBlockersSpecify	Char	1	\$1.	Plasma sample collected
70	Corticosteroids	Char	2	\$2.	Currently taking corticosteroids (e.g. prednisone)
71	systemicsteroids	Char	2	\$2.	Does the participant currently use immunosuppressive or immunomodulatory therapies including pharmacologic doses of systemic steroids
72	SteroidsSpecify	Char	1	\$1.	Currently taking steroids

Num	Variable	Type	Len	Format	Label
73	Diphenylhydantoin	Char	2	\$2.	Currently taking diphenylhydantoin
74	ParticipantUsingImmunosuppressi	Char	2	\$2.	Is the participant currently using immunosuppressive or immunomodulatory therapies or systemic glucocorticoids
75	ImmunosuppressiveTherapies	Char	3	\$3.	Currently taking any medications immunosuppressives or immunomodulatory therapies
76	ImmunosuppressiveTherapiesSpec	Char	39	\$39.	Specify immunosuppressives or immunomodulatory therapies
77	Meglinitides	Char	1	\$1.	Meglinitides
78	Metformin	Char	1	\$1.	Metformin
79	Niacin	Char	2	\$2.	Currently taking niacin
80	ParticipantUsedInsulinOrOtherG2	Char	1	\$1.	If yes specify
81	OtherGlucoseLoweringAgents	Char	1	\$1.	Other glucose lowering agents
82	PotassiumDepletingDiuretics	Char	2		Currently taking potassium depleting diuretics
83	PotassiumDepletingDiureticsSp	Char	1		Specify potassium depleting diuretics
84	Thiazolidinediones	Char	1	\$1.	Thiazolidinediones
85	EverPositiveForDiabetesAntibod	Char	2	\$2.	Has the participant ever tested positive for diabetes autoantibodies
86	AntibodySampleCollected	Char	3	\$3.	Antibodies sample collected
87	Antibodycomment	Char	21	\$21.	Antibodies comment
88	BlloodForDNASampleCollected	Char	3	\$3.	Whole blood for DNA sample collected
89	BlloodForDNAComment	Char	1	\$1.	Whole blood for DNA comment
90	BloodForCellsSampleCollected	Char	3	\$3.	Whole blood for cells sample collected
91	BloodForCellsComment	Char	1	\$1.	Whole blood for cells comment
92	BloodForRNASampleCollected	Char	3	\$3.	Whole blood for RNA sample collected
93	BloodForRNAComment	Char	1	\$1.	Whole blood for RNA comment
94	HLASamplesCollected	Char	3	\$3.	HLA sample collected
95	HLAComment	Char	23	\$23.	HLA comment
96	HbA1cSamplesCollected	Char	3	\$3.	HbA1c sample collected
97	HbA1cComment	Char	23	\$23.	HbA1c comment
98	OGTTSampleCollected	Char	3	\$3.	OGTT sample collected
99	OGTTComment	Char	57	\$57.	OGTT comment
100	PlasmaSampleCollected	Char	3	\$3.	Plasma sample collected
101	PlasmaComment	Char	1	\$1.	Plasma sample comment
102	SerumForProteomicsSampleCollec	Char	3	\$3.	Serum for proteomics sample collected
103	SerumForProteomicsComment	Char	1	\$1.	Serum for proteomics comment
104	SerumMechanisticSerumSampleCol	Char	1	\$1.	Mechanistic serum sample collected
105	SerumMechanisticSerumComment	Char	1	\$1.	Mechanistic serum sample comment
106	WholeBloodPBMCPlasmaSampleColl	Char	1	\$1.	Whole blood pbmc/plasma sample collected
107	WholeBloodPBMCPlasmaComment	Char	1	\$1.	Whole blood pbmc/plasma comment
108	ParticipantHasOneRelativeWithT	Char	3	\$3.	Does the participant have at least one blood relative living or deceased with type 1 diabetes T1D
109	YESSpecify	Char	47	\$47.	Specify blood relative living or deceased with type 1 diabetes T1D
110	DateConsentSignedDay	Num	8		Informed consent form signed day

Num	Variable	Type	Len	Format	Label
111	DateConsentSignedMonth	Char	3	\$3.	Informed consent form signed month
112	DateConsentSignedYear	Num	8		Informed consent form signed year
113	DateSignedNEWInformedConsentFo	Num	8		New informed consent form signed day
114	DateSignedNEWInformedConsentFo2	Char	3	\$3.	New informed consent form signed month
115	DateSignedNEWInformedConsentFo3	Num	8		New informed consent form signed year
116	MechanisticSampleCollectionDay	Num	8		Mechanistic sample collection day
117	MechanisticSampleCollectionMon	Char	3	\$3.	Mechanistic sample collection month
118	MechanisticSampleCollectionYea	Num	8		Mechanistic sample collection year
119	ProtocolVersion	Num	8		Protocol version
120	SamplesCollectionDay	Num	8		Samples collection day
121	SamplesCollectionMonth	Char	3	\$3.	Samples collection month
122	SamplesCollectionYear	Num	8		Samples collection year

Data Set Name: tn01_nh14c_contchangemonitor.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	DateControlBecameAutoantibodyP	Num	8		Date control participant became Autoantibody positive day
5	DateControlBecameAutoantibodyP2	Char	3	\$3.	Date control participant became Autoantibody positive month
6	DateControlBecameAutoantibodyP3	Num	8		Date control participant became Autoantibody positive year
7	WasTheParticipantNotified	Char	3	\$3.	Was the participant notified of their change in autoantibody positive status
8	DoesTheParticipantWishToContin	Char	3	\$3.	Does the participant wish to continue in the Pathway to Prevention Study as an Ab positive participant

Data Set Name: tn01_pathwaytoprevention.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	ProtocolVersion	Num	8		ProtocolVersion
5	CurrentPhase	Char	39	\$39.	On which study phase is this participant currently enrolled
6	TN01ControlSubjectAnnualorSemi	Char	22	\$22.	TN01 Control Subject Annual or SemiAnnual Monitoring

Data Set Name: tn01_permanentsitetransfer.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Effective date for transfer
3	Visit	Char	8	\$8.	Visit
4	Old_Site_Number	Char	91		Old Primary Site Number
5	Current_Site_Number	Char	91		Current Site Number
6	Reason_for_Transfer	Char	100	\$100.	Reason for Transfer

Data Set Name: tn01_protocoldeviation.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	DeviationDay	Num	8		Deviation day
5	DeviationMonth	Char	3		Deviation month
6	DeviationYear	Num	8		Deviation year
7	ProtcolDeviationDay	Num	8		Protocol deviation day
8	ProtcolDeviationMonth	Char	3		Protocol deviation month
9	ProtcolDeviationYear	Num	8		Protocol deviation year
10	SubjectRandomizedIneligibilityA	Char	3		If ineligible subject randomized checked approved by Eligibility Committee
11	TestingErrorProcedure	Char	1		Testing procedure error
12	RequiredBloodCollectionProcedu	Char	1		Blood collection not completed
13	ProtocolDeviationSpecify	Char	119		Specify other deviation
14	Deviation	Char	1		Protocol deviation
15	DeviationError	Char	49		Deviation error
16	DeviationReportedFor	Char	6		Reason
17	PInotified	Char	3		was the PI notified of deviation
18	ProtocolDeviation	Char	87		Protocol Deviation
19	ProtocolDeviation2	Char	83		Protocol Deviation
20	ProtocolDeviationApprovedByElg	Char	3		Was protocol deviation approved by the Eligibility Committee
21	TN16ProtocolDeviation	Char	88		TN16 Protocol deviation
22	CorrectiveActionTaken	Char	1698		Corrective action taken if necessary depending on circumstances
23	DescribeCorrectionAction	Char	175		Describe corrective action taken
24	DescribeDeviation	Char	204		Describe deviation
25	DeviationCircumstances	Char	3445		Deviation circumstances
26	DeviationOccurenceSpecify	Char	1		Specify deviation occurrence
27	ExlcudedMedicationSpecify	Char	1		Specify excluded medication
28	ExplanProtocolDeviation	Char	1		Explain protocol deviation
29	PhiX174WeekNumber	Num	8		If PhiX174 Visit ONLY (i.e 6, 7, 8, 13, 14, 16, 53, 54, 58, 59, 60, 62 Record week number)
30	IfMiscellaneousSpecify	Char	292		If Miscellaneous specify
31	OtherSpecify	Char	116		Specify other
32	OtherSpecify2	Char	159		Other specify
33	OtherSpecify3	Char	1		Other specify
34	ProtocolChair	Char	1		If yes who was the protocol chair
35	ProtocolDeviationOtherSubcateg	Char	89		Protocol deviation other subcategory
36	StudyVisitCompletedFor	Char	13		Study visit this form being completed for
37	OtheYear	Num	8		Other year

Num	Variable	Type	Len	Format	Label
38	OtheMonth	Char	3		Other month
39	OtherDay	Num	8		Other day
40	CentralIRBORlocalIRB	Char	11		Do you use a central IRB or a local IRB for this protocol
41	centralIRBscriteria	Char	46		The PI has reviewed the central IRBs criteria for reporting events to the central IRB and determined the following
42	IfOTHER	Char	185		If OTHER a Specify deviation

Data Set Name: tn01_protocolversion.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Visit_Dt	Num	8	MMDDYY10.	Date of Visit
3	Visit	Char	48		Visit
4	ProtocolVersion	Char	16	\$16.	Protocol Version
5	SignedConsentFor2017Protocol	Char	3	\$3.	Has this participant signed the consent for this protocol

Data Set Name: tn01_registration.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Date_of_Registration	Num	8	MMDDYY10.	Date of Registration
3	Status	Char	20		Status
4	Date_of_Study_Start	Num	8	MMDDYY10.	Date of Study Start

Data Set Name: tn01_researchlabsbaa_cy04_12.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Date_of_Draw	Num	8	MMDDYY10.	Date of Draw
3	Event_Title	Char	100		Specimen Collection Form
4	Spec_Name	Char	250		Specimen Name
5	SampleMaskID	Char	10		Sample Mask ID#
6	Test_Name	Char	150		Test Name
7	Result	Char	1000		Result
8	Result_Type	Char	6		Result Type
9	Visit	Char	48		Visit
10	Date_at_Test_Results_Reported	Num	8	MMDDYY10.	Date at Test Results Reported
11	Date_at_Evaluation	Num	8	MMDDYY10.	Date at Sample Evaluation
12	Date_Received	Num	8	MMDDYY10.	Date when Sample Received at Lab
13	Date_Shipped	Num	8	MMDDYY10.	Date when Sample Shipped
14	LabID	Num	8		Numeric code to identify testing Lab

Data Set Name: tn01_researchlabsbaa_cy13_20.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Date_of_Draw	Num	8	MMDDYY10.	Date of Draw
3	Event_Title	Char	100		Specimen Collection Form
4	Spec_Name	Char	250		Specimen Name
5	SampleMaskID	Char	10		Sample Mask ID#
6	Test_Name	Char	150		Test Name
7	Result	Char	1000		Result
8	Result_Type	Char	6		Result Type
9	Visit	Char	48		Visit
10	Date_at_Test_Results_Reported	Num	8	MMDDYY10.	Date at Test Results Reported
11	Date_at_Evaluation	Num	8	MMDDYY10.	Date at Sample Evaluation
12	Date_Received	Num	8	MMDDYY10.	Date when Sample Received at Lab
13	Date_Shipped	Num	8	MMDDYY10.	Date when Sample Shipped
14	LabID	Num	8		Numeric code to identify testing Lab

Data Set Name: tn01_researchlabs_other.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MaskID	Num	8		Participant Mask ID#
2	Date_of_Draw	Num	8	MMDDYY10.	Date of Draw
3	Event_Title	Char	100		Specimen Collection Form
4	Spec_Name	Char	250		Specimen Name
5	SampleMaskID	Char	10		Sample Mask ID#
6	Test_Name	Char	150		Test Name
7	Result	Char	1000		Result
8	Result_Type	Char	6		Result Type
9	Visit	Char	48		Visit
10	Date_at_Test_Results_Reported	Num	8	MMDDYY10.	Date at Test Results Reported
11	Date_at_Evaluation	Num	8	MMDDYY10.	Date at Sample Evaluation
12	Date_Received	Num	8	MMDDYY10.	Date when Sample Received at Lab
13	Date_Shipped	Num	8	MMDDYY10.	Date when Sample Shipped
14	LabID	Num	8		Numeric code to identify testing Lab